US20120220980A1 - Transdermal Patch Containing Microneedles - Google Patents
Transdermal Patch Containing Microneedles Download PDFInfo
- Publication number
- US20120220980A1 US20120220980A1 US13/036,096 US201113036096A US2012220980A1 US 20120220980 A1 US20120220980 A1 US 20120220980A1 US 201113036096 A US201113036096 A US 201113036096A US 2012220980 A1 US2012220980 A1 US 2012220980A1
- Authority
- US
- United States
- Prior art keywords
- support
- patch
- drug compound
- transdermal patch
- release member
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0038—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a channel at the side surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Definitions
- intravenous delivery is by injection directly into a blood vessel; intraperitoneal delivery is by injection into the peritoneum; subcutaneous delivery is under the skin; intramuscular delivery is into a muscle; and oral delivery is through the mouth.
- One of the easiest methods for drug delivery, and for collection of body fluids, is through the skin, Skin is composed of the epidermis, including the stratum corneum, the stratum granulosum, the stratum spinosum, and the stratum basale, and the dermis, containing, among other things, the capillary layer.
- the stratum corneum is a tough, scaly layer made of dead cell tissue that extends around 10-20 microns from the skin surface and has no blood supply. Because of the density of this layer of cells, moving compounds across the skin, either into or out of the body, can be very difficult.
- Invasive procedures such as use of needles or lances, can effectively overcome the barrier function of the stratum corneum.
- these methods suffer from several major disadvantages, including pain, local skin damage, bleeding, risk of infection at the injection site, and creation of contaminated needles or lances.
- These methods also usually require a trained administrator and are not suitable for repeated, long-term, or controlled use.
- drug delivery through the skin has been relatively imprecise in both location and dosage of the pharmaceutical.
- Some of the problems include movement of the patient during administration, delivery of incomplete dosages, difficulties in administering more than one pharmaceutical at the same time, and difficulties in delivering a pharmaceutical to the appropriate part of the skin.
- Drugs have traditionally been diluted to enable handling of the proper dosages. This dilution step can cause storage as well as delivery problems.
- Microneedles have been proposed for this purpose.
- the microneedles typically have a hollow shaft, similar to larger conventional medical needles, so that drug compounds may be delivered through the hollow shaft.
- Various mechanisms have been employed to initiate the flow of the drug compound through such devices.
- U.S. Pat. No. 6,611,707 to Prausnitz et al. describes a device having one or more drug reservoirs positioned over a housing that includes an array of hollow microneedles.
- a drug is delivered from the reservoir by applying a physical force, such as by pressing the top of the reservoir, to cause the drug to flow out through the microneedles.
- a physical force such as by pressing the top of the reservoir
- transdermal microneedle device that can easily deliver a drug compound without the need for active displacement mechanisms, such as pumps.
- a transdermal patch comprising a drug delivery assembly and a microneedle assembly.
- the drug delivery assembly comprises a reservoir for holding a drug compound and a rate control membrane that is in fluid communication with the reservoir.
- the microneedle assembly comprises a support having a first surface and a second surface, wherein an aperture, extends between the first surface of the support and the second surface of the support.
- the microneedle assembly further comprises a plurality of microneedles that extend outwardly from the second surface of the support. At least one of the microneedles contains a channel that is in fluid communication with the aperture of the support and has a cross-sectional dimension ranging from about 1 micrometer to about 100 micrometers.
- a release member that is generally impermeable to the drug compound is positioned adjacent to the rate control membrane of the drug delivery assembly and the first surface of the support of the microneedle assembly.
- the release member is configured to be at least partially separated from the rate control membrane of the drug delivery assembly and the support of the microneedle assembly when the patch is an active configuration.
- a method for transdermally delivering a drug compound comprises placing a patch adjacent to skin, the patch comprising a drug delivery assembly that comprises a reservoir that holds a drug compound and a rate control membrane; a microneedle assembly that comprises a support that defines an aperture, the microneedle assembly comprising a plurality of microneedles that extend outwardly from the support and contain a channel in fluid communication with the aperture of the support; and a release member that is generally impermeable to the drug compound and positioned adjacent to the rate control membrane and the support.
- the patch is activated to release the drug compound from the reservoir, through the rate control membrane and aperture of the support, and into the channel of the microneedles.
- the activation of the patch includes at least partially separating the release member from the rate control membrane and the support.
- FIG. 1 is a perspective view of one embodiment of the transdermal patch of the present invention prior to delivery of a drug compound
- FIG. 2 is a front view of the patch of FIG. 1 ;
- FIG. 3 is a perspective view of the patch of FIG. 1 in which the release member is partially withdrawn from the patch;
- FIG. 4 is a front view of the patch of FIG. 3 ;
- FIG. 5 is a perspective view of the transdermal patch of FIG. 1 after removal of the release member and during use;
- FIG. 6 is a front view of the patch of FIG. 5 ;
- FIG. 7 is a perspective view of another embodiment of a transdermal patch of the present invention prior to delivery of a drug compound
- FIG. 8 is a front view of the patch of FIG. 7 ;
- FIG. 9 is a perspective view of the patch of FIG. 7 in which the release member is partially peeled away from the patch;
- FIG. 10 is a front view of the patch of FIG. 9 ;
- FIG. 11 is a perspective view of the patch of FIG. 7 in which the release member is completely peeled away from the patch;
- FIG. 12 is a perspective view of the transdermal patch of FIG. 7 after removal of the release member and during use;
- FIG. 13 is a perspective view of a microneedle assembly that may be employed in one embodiment of the transdermal patch of the present invention.
- FIG. 14 is a cross-sectional view of the microneedle assembly of FIG. 13 , taken along lines 14 - 14 ;
- FIG. 15 is a top view of a microneedle assembly that may be employed in one embodiment of the transdermal patch of the present invention.
- FIG. 16 is a bottom view of a microneedle assembly that may be employed in one embodiment of the transdermal patch of the present invention.
- FIGS. 17 and 18 are partial cross-sectional views of microneedle assemblies that may be formed in accordance with an embodiment of the present invention.
- FIG. 19 is a cross-sectional view of a microneedle assembly in accordance with an embodiment of the present invention.
- FIG. 20 is a top view of another microneedle assembly that may be formed in accordance with an embodiment of the present invention.
- FIG. 21 is a perspective view of yet another embodiment of a transdermal patch of the present invention prior to delivery of a drug compound.
- the present invention is directed to a transdermal patch that can easily deliver a controlled volume of a fluidic drug compound to the skin.
- the patch contains a microneedle assembly that is configured to be placed in fluid communication with a drug delivery assembly.
- the microneedle assembly contains a support and a plurality of microneedles that extend outwardly from the support.
- the microneedles are formed with one or more channels of a certain dimension such that passive capillary flow drives the flow of the drug compound.
- the drug delivery system contains a reservoir for the drug compound that is in fluid communication with a rate control membrane that helps control the flow rate of the drug compound by modulating its pressure downstream from the reservoir.
- a release member is also positioned adjacent to the microneedle and drug delivery assemblies.
- the release member acts as a barrier to the flow of the drug compound and thus inhibits premature leakage.
- the patch can initially be provided in an “inactive” configuration in which the drug compound is securely retained.
- the patch can simply be activated by at least partially separating (e.g., detaching, rupturing, etc.) the release member from the drug delivery assembly and the microneedle assembly.
- the flow of the drug compound can be induced “passively”—i.e., without the need for conventional active displacement mechanisms, such as liquid pumps, actuators, plungers, finger pressure, etc.
- the drug delivery assembly of the transdermal patch contains a reservoir that can initially retain a drug compound.
- the term “reservoir” generally refers to a designated area or chamber configured to retain a fluidic drug compound.
- the reservoir may be an open volume space, gel, solid structure, etc. Nevertheless, in most embodiments, the reservoir is a solid matrix through which the drug compound is capable of flowing.
- the selection of the desired materials for the matrix typically depends on the solubility and diffusivity of the target drug compound and the time during which release is sought.
- the solid matrix is generally impermeable to the compound, and the material used to form the matrix is selected so that the drug compound is able to diffuse therethrough.
- the solid matrix may be permeable or semi-permeable to the drug compound so that it can simply flow through its pores.
- solid matrices include porous fiber webs (e.g., woven or nonwoven), apertured films, foams, sponges, etc.
- polymeric materials are often used to form the solid matrix, such as silicones, acrylic resins, acetate copolymers (e.g., ethylene vinyl acetate), plasticized polyvinyl acetate/polyvinyl chloride resins, plasticized hydrolyzed polyvinyl alcohol, rubber-based adhesives (e.g., polyisobutylenes extended with a solvent such as mineral oil), plasticized polyvinyl chloride, polyethylene glycols and polypropylene glycols of varying molecular weights, cellulose esters, polyolefins; etc.
- silicones e.g., acrylic resins, acetate copolymers (e.g., ethylene vinyl acetate), plasticized polyvinyl acetate/polyvinyl chloride resins, plasticized hydrolyzed polyvinyl alcohol, rubber-based adhesives (e.g., polyisobutylenes extended with a solvent such as mineral oil), plasticized polyvinyl chloride, polyethylene glycols
- Suitable compounds may include, for instance, proteinaceous compounds, such as insulin, immunoglobulins (e.g., IgG, IgM, IgA, IgE), TNF- ⁇ , antiviral medications, etc.; polynucleotide agents, such as plasmids, siRNA, RNAi, nucleoside anticancer drugs, vaccines, etc.; small molecule agents, such as alkaloids, glycosides, phenols, etc.; anti-infection agents, hormones, drugs regulating cardiac action or blood flow, pain control; and so forth.
- proteinaceous compounds such as insulin, immunoglobulins (e.g., IgG, IgM, IgA, IgE), TNF- ⁇ , antiviral medications, etc.
- polynucleotide agents such as plasmids, siRNA, RNAi, nucleoside anticancer drugs, vaccines, etc.
- small molecule agents such as alkaloids, glycosides, phenols, etc.
- agents includes anti-Angiogenesis agents, anti-depressants, antidiabetic agents, antihistamines, anti-inflammatory agents, butorphanol, calcitonin and analogs, COX-II inhibitors, dermatological agents, dopamine agonists and antagonists, enkephalins and other opioid peptides, epidermal growth factors, erythropoietin and analogs, follicle stimulating hormone, glucagon, growth hormone and analogs (including growth hormone releasing hormone), growth hormone antagonists, heparin, hirudin and hirudin analogs such as hirulog, IgE suppressors and other protein inhibitors, immunosuppressives, insulin, insulinotropin and analogs, interferons, interleukins, leutenizing hormone, leutenizing hormone releasing hormone and analogs, monoclonal or polyclonal antibodies, motion sickness preparations, muscle relaxants, narcotic analgesics, nicotine, non-steroid anti
- the patch of the present invention may be particularly beneficial in delivering high molecular weight drug compounds that were previously difficult to deliver via transdermal delivery.
- high molecular weight generally refers to compounds having a molecular weight of about 1 kiliDalton (“kDa”) or more, in some embodiments about 10 kDa or more, in some embodiments about 20 kDa to about 250 kDa, and in some embodiments, from about greater than about 40 kDa to about 150 kDa.
- the patch may be utilized in treatment of a chronic condition, such as rheumatoid arthritis (“RA”), to deliver a steady flow a drug to a subject in need thereof.
- RA drug compounds may include symptom suppression compounds, such as analgesics and anti-inflammatory drugs including both steroidal and non-steroidal anti-inflammatory drugs (NSAID), as well as disease-modifying antirheumatic drugs (“DMARD”).
- NSAID steroidal and non-steroidal anti-inflammatory drugs
- DMARD disease-modifying antirheumatic drugs
- the patch can include and deliver symptom suppression compounds, such as analgesics and anti-inflammatory drugs, as well as DMARD compounds, including biological DMARDs.
- symptom suppression compounds such as analgesics and anti-inflammatory drugs
- DMARD compounds including biological DMARDs.
- RA drugs can be delivered at a steady concentration over a sustained period.
- the patch can prevent the initial burst of concentration common when utilizing previously known methods for delivery of RA drugs, including oral delivery and injection.
- RA drugs that may be incorporated in the patch can include, without limitation, one or more analgesics, anti-inflammatories, DMARDs, herbal-based drugs, and combinations thereof.
- Specific compounds can, of course, fall under one or more of the general categories described herein. For instance, many compounds function as both an analgesic and an anti-inflammatory; herbal-based drugs can likewise function as a DMARD as well as an anti-inflammatory.
- multiple compounds that can fall under a single category can be incorporated in the patch.
- the patch can include multiple analgesics, such as acetaminophen with codeine, acetaminophen with hydrocodone (vicodin), and so forth.
- analgesics and/or NSAIDs include analgesics available over the counter (OTC) at relatively low dosages including acetamide (acetaminophen or paracetamol), acetylsalicylic acid (aspirin), ibuprofen, ketoprofen, naproxen and naproxen sodium, and so forth.
- OTC counter
- Prescription analgesics and/or anti-inflammatories can include, without limitation, OTC analgesics at concentrations requiring a prescription, celecoxib, sulindac, oxaprozin, salsalate, piroxicam, indomethacin, etodolac, meloxicam, nabumetone, keteroloc and ketorolac tromethamine, tolmetin, diclofenac, diproqualone, and diflunisal.
- Narcotic analgesics can include codeine, hydrocodone, oxycodone, fentanyl, and propoxyphene.
- DMARDs can encompass both small molecule drugs and biological agents. DMARDs may be chemically synthesized or may be produced through genetic engineering processes (e.g., recombinant techniques). Chemically synthesized DMARDs encompassed herein include, without limitation, azathioprine, cyclosporine (ciclosporin, cyclosporine A), D-penicillamine, gold salts (e.g., auranofin, Na-aurothiomalate (Myocrism), chloroquine, hydroxychloroquine, leflunomide, methotrexate, minocycline, sulphasalazine (sulfasalazine), and cyclophosphamide.
- azathioprine e.g., auranofin, Na-aurothiomalate (Myocrism)
- chloroquine hydroxychloroquine, leflunomide
- methotrexate minocycline
- Biological DMARDs include, without limitation, TNF- ⁇ blockers such as etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), certolizamab pego (Cimzia®) and golumumab (SimponiTM); IL-1 blockers such as anakinra (Kineret®); monoclonal antibodies against B cells including rituximab (Rituxan®); T cell costimulation blockers such as abatacept (Orencia®), and IL-6 blockers such as tocilizumab (RoActemra®, Actemra®); a calcineurin inhibitor such as tacrolimus (Prograf®).
- TNF- ⁇ blockers such as etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), certolizamab pego (Cim
- the patch may also incorporate multiple RA drugs.
- the patch can include a combination of DMARDs in addition to an analgesic and/or an anti-inflammatory drug.
- DMARDs include, for example, methotrexate in combination with hydroxychloroquine, methotrexate in combination with sulfasalazine, sulfasalazine in combination with hydroxychloroquine, and all three of these DMARDs together, i.e., hydroxychloroquine, methotrexate, and sulfasalazine.
- the patch may employ a plurality of reservoirs for storing multiple materials for delivery.
- the reservoirs may be positioned adjacent to each other, either in a vertical or horizontal relationship.
- a first reservoir may contain a drug compound and a second reservoir may contain an excipient (e.g., delivery vehicle, such as alcohols, water, etc.; buffering agents; and so forth).
- the first reservoir may contain a lyophilized powder of the drug compound (e.g., RA drug) and the second reservoir may contain an aqueous solution for reconstituting the powder.
- multiple reservoirs may be employed that each contains a drug compound. Regardless, the different materials may be mixed prior to delivery.
- the drug delivery assembly also contains a rate control membrane that is in fluid communication with the drug reservoir.
- the rate control membrane can help slow down the flow rate of the drug compound upon its release. Specifically, fluidic drug compounds passing from the drug reservoir to the microneedle assembly may experience a drop in pressure that results in a reduction in flow rate. If this difference is too great, some backpressure may be created that can impede the flow of the compound and potentially overcome the capillary pressure of the fluid through the microfluidic channels. Thus, the use of the rate control membrane can ameliorate this difference in pressure and allow the drug compound to be introduced into the microneedle at a more controlled flow rate.
- the particular materials, thickness, etc. of the rate control membrane can vary based on multiple factors, such as the viscosity of the drug compound, the desired delivery time, etc.
- the rate-controlling membrane may be fabricated from permeable, semi-permeable or microporous materials that are known in the art to control the rate of drug compounds and having a permeability to the permeation enhancer lower than that of drug reservoir.
- the material used to form the rate control membrane may have an average pore size of from about 50 nanometers to about 5 micrometers, in some embodiments from about 100 nanometers to about 2 micrometers, and in some embodiments, from about 300 nanometers to about 1 micrometer (e.g., about 600 nanometers).
- Suitable membrane materials include, for instance, fibrous webs (e.g., woven or nonwoven), apertured films, foams, sponges, etc., which are formed from polymers such as polyethylene, polypropylene, polyvinyl acetate, ethylene n-butyl acetate and ethylene vinyl acetate copolymers. Such membrane materials are also described in more detail in U.S. Pat. Nos.
- the drug delivery assembly may contain additional layers or materials that provide various benefits to the resulting transdermal patch.
- the assembly includes an adhesive layer that can help facilitate the attachment of the patch to a user's skin during use.
- the adhesive layer is often disposed over the reservoir.
- the adhesive layer typically employs an adhesive coated onto a backing material.
- the backing may be made of a material that is substantially impermeable to the drug compound, such as polymers, metal foils, etc. Suitable polymers may include, for instance, polyethylene terephthalate, polyvinylchloride, polyethylene, polypropylene, polycarbonate, polyester, and so forth.
- the adhesive may be a pressure-sensitive adhesive as is known in the art. Suitable adhesives may include, for instance, solvent-based acrylic adhesives, solvent-based rubber adhesives, silicone adhesives, etc.
- the transdermal patch of the present invention also contains a microneedle assembly that is capable of being placed in fluid communication with the drug delivery assembly described above.
- the microneedle assembly contains a plurality of microneedles that extend outwardly from a support. Referring to FIGS. 13-14 , for example, one particular embodiment of a microneedle assembly 310 is shown in more detail that contains a plurality of microneedles 318 that extend from a support 312 .
- the support 312 may be constructed from a rigid or flexible sheet of metal, ceramic, plastic or other material.
- the support 312 can vary in thickness to meet the needs of the transdermal patch, such as about 1000 micrometers or less, in some embodiments from about 1 to about 500 micrometers, and in some embodiments, from about 10 to about 200 micrometers.
- an aperture 328 may be formed in the support 312 that extends through a first surface 314 and a second opposing surface 316 .
- the microneedles 318 extend from the second surface 316 , although in other embodiments the microneedles 318 may extend from the first surface 314 or elsewhere.
- microneedles 318 shown in the figures is for illustrative purposes only.
- the actual number of microneedles used in the patch may, for example, range from about 500 to about 10,000, in some embodiments from about 2,000 to about 8,000, and in some embodiments, from about 4,000 to about 6,000.
- the size and shape of the microneedles 318 may also vary as desired.
- the microneedles 318 of FIGS. 13 and 14 have an overall conical shape. In alternative embodiments, however, the microneedles 318 may have an overall pyramidal shape or a cylindrical portion upon which is positioned a conical portion having a tip, such as is shown in FIGS. 17-18 .
- the microneedle 318 typically includes a base 320 and a tip 322 .
- the base 320 is the portion of the microneedle 318 that is proximate to the second surface 316 of the support 312 .
- the tip 322 of the microneedle 318 is the point of the microneedle 318 that is furthest from the base 320 .
- the tip 322 may be variously formed, it typically has a radius that is less than or equal to about 1 micrometer.
- the microneedles 318 are typically of a length sufficient to penetrate the stratum corneum and pass into the epidermis, but not penetrate through the epidermis and into the dermis in applications where it is desirable to minimize pain.
- the microneedles have a length (from their tip 322 to their base 320 ) of about 500 micrometers or less, in some embodiments from 1 to about 400 micrometers, and in some embodiments, from about 50 to about 350 micrometers.
- the microneedles 318 may be arranged on the substrate in a variety of patterns, and such patterns may be designed for a particular use.
- the microneedles may be spaced apart in a uniform manner, such as in a rectangular or square grid or in concentric circles. The spacing may depend on numerous factors, including height and width of the microneedles 318 , as well as the amount and type of substance that is intended to be moved through the microneedles.
- microneedles 318 While a variety of arrangements of microneedles is useful in the present invention, a particularly useful arrangement of microneedles 318 is a “tip-to-tip” spacing between microneedles of about 50 micrometers or more, in some embodiments about 100 to about 800 micrometers, and in some embodiments, from about 200 to about 600 micrometers.
- the microneedles 318 may be formed of various substances such as, for example, polymers, ceramics and metals. While numerous processes may be used to manufacture microneedles according to the present invention, a suitable production system is MEMS (Micro-Electro-Mechanical Systems) technology and microfabrication processes.
- MEMS Micro-Electro-Mechanical Systems
- MEMS is capable of forming micromechanical and other elements such as semiconductors on a single silicon substrate using microfabrication processes such as etching, micromachining or other processes.
- the support 312 may be manufactured from silicon, the microneedles being subsequently formed by a microetching process. Micromolding techniques may also be used to form the microneedles 318 and support 312 .
- the microneedles generally define at least one channel that is in fluidic communication with at least a portion of the aperture of the support.
- the dimensions of the channel are specifically selected in the present invention to induce capillary flow of the drug compound.
- Capillary flow generally occurs when the adhesive forces of a fluid to the walls of a channel are greater than the cohesive forces between the liquid molecules.
- capillary pressure is inversely proportional to the cross-sectional dimension of the channel and directly proportional to the surface tension of the liquid, multiplied by the cosine of the contact angle of the fluid in contact with the material forming the channel.
- the cross-sectional dimension (e.g., width, diameter, etc.) of the channel may be selectively controlled, with smaller dimensions generally resulting in higher capillary pressure.
- the cross-sectional dimension of the channel typically ranges from about 1 micrometer to about 100 micrometers, in some embodiments from about 5 micrometers to about 50 micrometers, and in some embodiments, from about 10 micrometers to about 30 micrometers.
- the dimension may be constant or it may vary as a function of the length of the channel.
- the length of the channel may also vary to accommodate different volumes, flow rates, and dwell times for the drug compound.
- the length of the channel may be from about 10 micrometers to about 800 micrometers, in some embodiments from about 50 micrometers to about 500 micrometers, and in some embodiments, from about 100 micrometers to about 300 micrometers.
- the cross-sectional area of the channel may also vary.
- the cross-sectional area may be from about 50 square micrometers to about 1,000 square micrometers, in some embodiments from about 100 square micrometers to about 500 square micrometers, and in some embodiments, from about 150 square micrometers to about 350 square micrometers.
- the aspect ratio (length/cross-sectional dimension) of the channel may range from about 1 to about 50, in some embodiments from about 5 to about 40, and in some embodiments from about 10 to about 20. In cases where the cross-sectional dimension (e.g., width, diameter, etc.) and/or length vary as a function of length, the aspect ratio is determined from the average dimensions.
- the illustrated microneedles 318 contain at least one channel 330 .
- the channel may be located in a variety of different positions, such as in the interior of the channel, on an exterior surface, etc.
- the channel 330 is located on an exterior surface 324 of the microneedle 318 .
- the cross-section of the channel 330 as shown in FIGS. 15-16 , is substantially U-shaped.
- the channel 330 may also be arcuate or have any other configuration suitable for moving a substance therethrough, such as, for example, V-shaped or C-shaped.
- a pathway 326 is formed by the channel 330 and the aperture 328 , which meet at a junction 332 that is generally located in the plane of the second surface 316 .
- Each microneedle 318 may deliver or extract drug compounds through the skin via the pathway 326 , as depicted in FIG. 14 .
- the pathway 326 enables the compound to flow from the first surface 314 through the aperture 328 , the junction 332 and exiting into the channel 330 .
- an aperture 328 is aligned with a single channel 330 via a junction 332 .
- a single aperture may feed two or more separate channels 330 .
- the channel 330 may extend from the junction 332 at the base 320 of the microneedle to the tip 322 , as depicted in FIGS. 13 and 14 . In other embodiments, the channel 330 may not extend the full length of the microneedle 318 to the tip 322 .
- Each microneedle 318 may include more than one channel 330 , as seen in the embodiments of FIGS. 17-19 . Alternate embodiments may include more channels if desired.
- the channel 330 may be variously positioned on the exterior surface 324 , forming a substantially linear path from the base 320 towards the tip 322 , or forming a winding or circuitous path along the exterior surface 324 . In microneedles where two or more channels are present, the channels 330 may be variously spaced around the microneedle 318 in a symmetrical or asymmetrical manner.
- FIG. 16 is a view looking at the first surface 314 of the microneedle assembly 310 , which shows the junction 332 that is formed in the pathway 326 by the overlapping portions of the aperture 328 and the channel 330 .
- FIG. 15 is a view looking down onto the second surface 316 of the microneedle 318 , showing the junction 332 as seen from that portion of the microneedle assembly 310 , which may be in contact with the skin of a user.
- the junction 332 may vary in area between pathways 326 on a given microneedle 318 , and may vary between microneedles 318 on a given microneedle assembly 310 .
- the area of the junction 332 may vary widely, and will depend on factors such as, for example, the diameter of the microneedle 318 , the viscosity of the substance to be moved through the pathway 326 and the quantity of substance to be delivered.
- the area of the junction 332 at the second surface 316 is greater than or equal to about 100 square microns, although smaller areas may also be acceptable for use in the present invention. In other embodiments, the area of the junction 332 at the second surface 316 may be equal to about 150 square microns or greater.
- FIG. 17 illustrates embodiments of the microneedle 318 in which the aperture 328 and channel 330 have sides that are not only coextensive with each other but may also be planar for at least some distance along the length of the pathway 326 .
- FIGS. 18-19 illustrate an embodiment where a single aperture 328 is aligned with more than one channel 330 on a particular microneedle 318 .
- FIG. 20 is a view of the second surface 316 of the microneedle assembly 310 shown in FIG. 19 , illustrating the alignment of the microneedle 318 , the channels 330 , the aperture 328 and the junctions 332 .
- a release member is initially positioned adjacent to the microneedle assembly and the drug delivery assembly so that it is adjacent to the support of the microneedle assembly and the rate control membrane of the drug delivery assembly. It should be understood, however, that the release layer need not contact such layers, and that other layers may be in fact be positioned between the release member and the support and/or rate control membrane.
- the release member is made of a material that is substantially impermeable to the drug compound, such as a polymeric material, metal, etc. The material is also desirably hydrophobic. Suitable polymeric materials may include, for instance, polyethylene terephthalate, polyvinylchloride, polyethylene, polypropylene, polycarbonate, polyester, metal foils, and so forth.
- the release member can initially seal the aperture in the support and thus limit the flow of the drug compound therethrough.
- a force may be applied by the user to at least partially separate the release member, thereby breaking the seal.
- the separation of the release member may be accomplished in a variety of ways. For instance, a portion of the release member may simply be ruptured. Any of a variety of known techniques for forming a rupturable layer may be employed in the present invention.
- the release member may be bonded about its perimeter. The strength of the bonds may exceed the tensile strength of the release member so that when a tensile force is applied, an inner portion of the substrate ruptures while the bonded perimeter remains in tact.
- FIGS. 1-6 one embodiment of a release member is shown that is configured to be detached from the transdermal patch to initiate the flow of the drug compound.
- FIGS. 1-2 show a transdermal patch 100 that contains a drug delivery assembly 170 and a microneedle assembly 180 .
- the drug delivery assembly 170 includes a reservoir 106 positioned adjacent to a rate control membrane 108 , such as described above.
- the assembly 170 also contains an adhesive layer 104 that is positioned adjacent to the reservoir 106 .
- the microneedle assembly 180 likewise includes a support 112 from which extends a plurality of microneedles 130 having channels 131 , such as described above.
- the layers of the drug delivery assembly 170 and/or the microneedle assembly 180 may be attached together if desired using any known bonding technique, such as through adhesive bonding, thermal bonding, ultrasonic bonding, etc.
- the patch 100 also contains a release member 110 that is positioned between the drug delivery assembly 170 and the microneedle assembly 180 . While the release member 110 may optionally be bonded to the adjacent support 112 and/or rate control membrane 108 , it is typically desired that it is only lightly bonded, if at all, so that the release member 110 can be easily withdrawn from the patch 100 . If desired, the release member 110 may also contain a tab portion 171 ( FIGS. 1-2 ) that extends at least partly beyond the perimeter of the patch 100 to facilitate the ability of a user to grab onto the member and pull it in the desired direction. In its “inactive” configuration as shown in FIGS.
- the drug delivery assembly 170 of the patch 100 securely retains a drug compound 107 so that it does not flow to any significant extent into the microneedles 130 .
- the patch can be “activated” by simply applying a force to the release member so that it is detached from the patch.
- FIGS. 3-4 one embodiment for activating the patch 100 is shown in which the release member 110 is pulled in a longitudinal direction. The entire release member 110 may be removed as shown in FIGS. 5-6 , or it may simply be partially detached as shown in FIGS. 3-4 . In either case, however, the seal previously formed between the release member 110 and the aperture (not shown) of the support 112 is broken.
- a drug compound 107 can begin to flow from the drug delivery assembly 170 and into the channels 131 of the microneedles 130 via the support 112 .
- An exemplary illustration of how the drug compound 107 flows from the reservoir 106 and into the channels 131 is shown in FIGS. 5-6 .
- the flow of the drug compound 107 is passively initiated and does not require any active displacement mechanisms (e.g., pumps).
- the detachment of the release member immediately initiates the flow of the drug compound to the microneedles because the drug delivery assembly is already disposed in fluid communication with the microneedle assembly. In certain embodiments, however, it may be desired to provide the user with a greater degree of control over the timing of the release of the drug compound. This may be accomplished by using a patch configuration in which the microneedle assembly is not initially in fluid communication with the drug delivery assembly. When it is desired to use the patch, the user may physically manipulate the two separate assemblies into fluid communication. The release member may be separated either before or after such physical manipulation occurs.
- FIGS. 7-12 one particular embodiment of a patch 200 is shown.
- FIGS. 7-8 illustrate the patch 200 before use, and shows a first section 250 formed by a microneedle assembly 280 and a second section 260 formed by a drug delivery assembly 270 .
- the drug delivery assembly 270 includes a reservoir 206 positioned adjacent to a rate control membrane 208 as described above. Although optional, the assembly 270 also contains an adhesive layer 204 that is positioned adjacent to the reservoir 206 .
- the microneedle assembly 280 likewise includes a support 212 from which extends a plurality of microneedles 230 having channels 231 , such as described above.
- the support 212 and the rate control membrane 208 are initially positioned horizontally adjacent to each other, and a release member 210 extends over the support 212 and the rate control member 208 .
- a release member 210 extends over the support 212 and the rate control member 208 .
- the release member 210 releasably attached to the support 212 and the rate control membrane 208 with an adhesive (e.g., pressure-sensitive adhesive).
- an adhesive e.g., pressure-sensitive adhesive
- the drug delivery assembly 270 of the patch 200 securely retains a drug compound 207 so that it does not flow to any significant extent into the microneedles 230 .
- the release member 210 may be peeled away and removed, such as illustrated in FIGS.
- the second section 260 may be folded about a fold line “F” as shown by the directional arrow in FIG. 11 so that the rate control member 208 is positioned vertically adjacent to the support 212 and in fluid communication therewith.
- the first section 250 may be folded. Regardless, folding of the sections 250 and/or 260 initiates the flow of a drug compound 207 from the drug delivery assembly 270 and into the channels 231 of the microneedles 230 via the support 212 (See FIG. 12 ).
- a patch 400 that employs a drug delivery assembly 470 and a microneedle assembly 480 .
- the drug delivery assembly 470 includes two separate reservoirs 406 a and 406 b , respectively, such as described above.
- the second reservoir 406 b may, for example, contain a powdered drug compound 407 (e.g., RA drug) and the first reservoir 406 a may contain a liquid solution (not shown) for reconstituting the powder.
- a powdered drug compound 407 e.g., RA drug
- a first release member 410 b may be separated from the reservoirs 406 a and 406 b by any of the techniques mentioned above, such as by rupturing it or pulling it in the direction of the arrow shown in FIG. 21 . In any event, separation of the first release member 410 b causes the ingredients in the reservoirs to mix together to form a solution form of the drug compound. Thereafter, a second release member 410 a may likewise be separated from a rate control membrane 408 and a support 412 of the microneedle assembly 480 . This causes the drug compound to flow from the rate control membrane 408 into channels 431 of the microneedles 430 .
- the patch 400 may also contain an adhesive layer 404 to help adhere it to the skin of a user.
- the release member can provide a variety of different benefits to the resulting transdermal patch. For instance, because the release member is easily separated, flow of the drug compound may be initiated by a user without necessarily requiring the aid of a medical professional. Furthermore, because it is configured for separation, the extent to which the release member is bonded to adjacent layers is generally minimized, if at all. Such a lightly bonded release member may leave a small space between the layers to which it is adjacent when it is separated (partially or completely) therefrom. Notably, the present inventors have discovered that this small space may form a microreservoir that temporarily holds the drug compound before it enters the microneedle assembly.
- this microreservoir is believed to further assist in the capillary flow through the channels of the microneedles.
- one embodiment of such a microreservoir is shown in more detail in FIGS. 5-6 as element 190 .
- the thickness of the microreservoir 190 is typically from about 50 nanometers to about 50 micrometers, in some embodiments from about 100 nanometers to about 10 micrometers, and in some embodiments, from about 200 nanometers to about 1 micrometer.
Abstract
Description
- The delivery of drugs to a patient is conventionally performed in a number of different ways. For example, intravenous delivery is by injection directly into a blood vessel; intraperitoneal delivery is by injection into the peritoneum; subcutaneous delivery is under the skin; intramuscular delivery is into a muscle; and oral delivery is through the mouth. One of the easiest methods for drug delivery, and for collection of body fluids, is through the skin, Skin is composed of the epidermis, including the stratum corneum, the stratum granulosum, the stratum spinosum, and the stratum basale, and the dermis, containing, among other things, the capillary layer. The stratum corneum is a tough, scaly layer made of dead cell tissue that extends around 10-20 microns from the skin surface and has no blood supply. Because of the density of this layer of cells, moving compounds across the skin, either into or out of the body, can be very difficult.
- Current techniques for delivering local pharmaceuticals through the skin include methods that use needles or other skin piercing devices and methods that do not use such devices. Those methods that do not use needles typically involve: (a) topical applications, (b) iontophoresis, (c) electroporation, (d) laser perforation or alteration, (e) carriers or vehicles, which are compounds that modify the chemical properties of either the stratum corneum and/or the pharmaceutical, (f) physical pretreatment of the skin, such as abrasion of the stratum corneum (e.g., repeatedly applying and removing adhesive tape), and (g) sonophoresis, which involves modifying the barrier function of stratum corneum by ultrasound. Invasive procedures, such as use of needles or lances, can effectively overcome the barrier function of the stratum corneum. However, these methods suffer from several major disadvantages, including pain, local skin damage, bleeding, risk of infection at the injection site, and creation of contaminated needles or lances. These methods also usually require a trained administrator and are not suitable for repeated, long-term, or controlled use. Additionally, drug delivery through the skin has been relatively imprecise in both location and dosage of the pharmaceutical. Some of the problems include movement of the patient during administration, delivery of incomplete dosages, difficulties in administering more than one pharmaceutical at the same time, and difficulties in delivering a pharmaceutical to the appropriate part of the skin. Drugs have traditionally been diluted to enable handling of the proper dosages. This dilution step can cause storage as well as delivery problems. Thus, it would be advantageous to be able to use small, precise volumes of pharmaceuticals for quick, as well as long-term, delivery through the skin.
- Microneedles have been proposed for this purpose. The microneedles typically have a hollow shaft, similar to larger conventional medical needles, so that drug compounds may be delivered through the hollow shaft. Various mechanisms have been employed to initiate the flow of the drug compound through such devices. U.S. Pat. No. 6,611,707 to Prausnitz et al., for example, describes a device having one or more drug reservoirs positioned over a housing that includes an array of hollow microneedles. A drug is delivered from the reservoir by applying a physical force, such as by pressing the top of the reservoir, to cause the drug to flow out through the microneedles. Unfortunately, due to their very small size, the hollow shafts of microneedles can break off when the physical force is applied. Further, the delivery of a drug compound that is initiated by such a physical force is sometimes too fast for achieving a controlled flow rate. U.S. Pat. No. 7,651,475 to Angel, et al. describes one attempt to overcome these problems by employing an actuator that pumps the drug compound between the reservoir and the body through the needles. While potentially helping to achieve a controlled flow rate, the use of such actuators (pumps) to induce flow is nevertheless cost prohibitive and overly complex, particularly when the product is intended for use by a person other than a medical professional.
- As such, a need currently exists for a transdermal microneedle device that can easily deliver a drug compound without the need for active displacement mechanisms, such as pumps.
- In accordance with one embodiment of the present invention, a transdermal patch is disclosed that comprises a drug delivery assembly and a microneedle assembly. The drug delivery assembly comprises a reservoir for holding a drug compound and a rate control membrane that is in fluid communication with the reservoir. The microneedle assembly comprises a support having a first surface and a second surface, wherein an aperture, extends between the first surface of the support and the second surface of the support. The microneedle assembly further comprises a plurality of microneedles that extend outwardly from the second surface of the support. At least one of the microneedles contains a channel that is in fluid communication with the aperture of the support and has a cross-sectional dimension ranging from about 1 micrometer to about 100 micrometers. A release member that is generally impermeable to the drug compound is positioned adjacent to the rate control membrane of the drug delivery assembly and the first surface of the support of the microneedle assembly. The release member is configured to be at least partially separated from the rate control membrane of the drug delivery assembly and the support of the microneedle assembly when the patch is an active configuration.
- In accordance with another embodiment of the present invention, a method for transdermally delivering a drug compound is disclosed. The method comprises placing a patch adjacent to skin, the patch comprising a drug delivery assembly that comprises a reservoir that holds a drug compound and a rate control membrane; a microneedle assembly that comprises a support that defines an aperture, the microneedle assembly comprising a plurality of microneedles that extend outwardly from the support and contain a channel in fluid communication with the aperture of the support; and a release member that is generally impermeable to the drug compound and positioned adjacent to the rate control membrane and the support. The patch is activated to release the drug compound from the reservoir, through the rate control membrane and aperture of the support, and into the channel of the microneedles. The activation of the patch includes at least partially separating the release member from the rate control membrane and the support.
- Other features and aspects of the present invention are described in more detail below.
- A full and enabling disclosure of the present invention, including the best mode thereof, directed to one of ordinary skill in the art, is set forth more particularly in the remainder of the specification, which makes reference to the appended figures in which:
-
FIG. 1 is a perspective view of one embodiment of the transdermal patch of the present invention prior to delivery of a drug compound; -
FIG. 2 is a front view of the patch ofFIG. 1 ; -
FIG. 3 is a perspective view of the patch ofFIG. 1 in which the release member is partially withdrawn from the patch; -
FIG. 4 is a front view of the patch ofFIG. 3 ; -
FIG. 5 is a perspective view of the transdermal patch ofFIG. 1 after removal of the release member and during use; -
FIG. 6 is a front view of the patch ofFIG. 5 ; -
FIG. 7 is a perspective view of another embodiment of a transdermal patch of the present invention prior to delivery of a drug compound; -
FIG. 8 is a front view of the patch ofFIG. 7 ; -
FIG. 9 is a perspective view of the patch ofFIG. 7 in which the release member is partially peeled away from the patch; -
FIG. 10 is a front view of the patch ofFIG. 9 ; -
FIG. 11 is a perspective view of the patch ofFIG. 7 in which the release member is completely peeled away from the patch; -
FIG. 12 is a perspective view of the transdermal patch ofFIG. 7 after removal of the release member and during use; -
FIG. 13 is a perspective view of a microneedle assembly that may be employed in one embodiment of the transdermal patch of the present invention; -
FIG. 14 is a cross-sectional view of the microneedle assembly ofFIG. 13 , taken along lines 14-14; -
FIG. 15 is a top view of a microneedle assembly that may be employed in one embodiment of the transdermal patch of the present invention; -
FIG. 16 is a bottom view of a microneedle assembly that may be employed in one embodiment of the transdermal patch of the present invention; -
FIGS. 17 and 18 are partial cross-sectional views of microneedle assemblies that may be formed in accordance with an embodiment of the present invention; -
FIG. 19 is a cross-sectional view of a microneedle assembly in accordance with an embodiment of the present invention; -
FIG. 20 is a top view of another microneedle assembly that may be formed in accordance with an embodiment of the present invention; and -
FIG. 21 is a perspective view of yet another embodiment of a transdermal patch of the present invention prior to delivery of a drug compound. - Repeat use of reference characters in the present specification and figures is intended to represent same or analogous features or elements of the invention.
- Reference now will be made in detail to various embodiments of the invention, one or more examples of which are set forth below. Each example is provided by way of explanation, not limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, may be used on another embodiment to yield a still further embodiment. Thus, it is intended that the present invention cover such modifications and variations.
- Generally speaking, the present invention is directed to a transdermal patch that can easily deliver a controlled volume of a fluidic drug compound to the skin. More particularly, the patch contains a microneedle assembly that is configured to be placed in fluid communication with a drug delivery assembly. The microneedle assembly contains a support and a plurality of microneedles that extend outwardly from the support. The microneedles are formed with one or more channels of a certain dimension such that passive capillary flow drives the flow of the drug compound. The drug delivery system contains a reservoir for the drug compound that is in fluid communication with a rate control membrane that helps control the flow rate of the drug compound by modulating its pressure downstream from the reservoir. A release member is also positioned adjacent to the microneedle and drug delivery assemblies. Prior to use, the release member acts as a barrier to the flow of the drug compound and thus inhibits premature leakage. In this manner, the patch can initially be provided in an “inactive” configuration in which the drug compound is securely retained. When it is desired to release the drug compound, the patch can simply be activated by at least partially separating (e.g., detaching, rupturing, etc.) the release member from the drug delivery assembly and the microneedle assembly. Notably, through the synergistic combination of features noted above, the flow of the drug compound can be induced “passively”—i.e., without the need for conventional active displacement mechanisms, such as liquid pumps, actuators, plungers, finger pressure, etc. This allows the patch to be placed on the skin before activation, thereby limiting potential spillage of the drug compound. The passive delivery of the drug compound is also simple and easy to use, which enables it to be used by a wide variety of consumers, not just medical professionals. Various embodiments of the present invention will now be described more detail below.
- A. Reservoir
- As indicated above, the drug delivery assembly of the transdermal patch contains a reservoir that can initially retain a drug compound. The term “reservoir” generally refers to a designated area or chamber configured to retain a fluidic drug compound. The reservoir may be an open volume space, gel, solid structure, etc. Nevertheless, in most embodiments, the reservoir is a solid matrix through which the drug compound is capable of flowing. The selection of the desired materials for the matrix typically depends on the solubility and diffusivity of the target drug compound and the time during which release is sought. In one embodiment, for example, the solid matrix is generally impermeable to the compound, and the material used to form the matrix is selected so that the drug compound is able to diffuse therethrough. In other embodiments, however, the solid matrix may be permeable or semi-permeable to the drug compound so that it can simply flow through its pores. Examples of such solid matrices include porous fiber webs (e.g., woven or nonwoven), apertured films, foams, sponges, etc. Regardless of its particular form, polymeric materials are often used to form the solid matrix, such as silicones, acrylic resins, acetate copolymers (e.g., ethylene vinyl acetate), plasticized polyvinyl acetate/polyvinyl chloride resins, plasticized hydrolyzed polyvinyl alcohol, rubber-based adhesives (e.g., polyisobutylenes extended with a solvent such as mineral oil), plasticized polyvinyl chloride, polyethylene glycols and polypropylene glycols of varying molecular weights, cellulose esters, polyolefins; etc.
- There is no particular limitation to the drug compounds that may be retained within the reservoir and employed in the patch of the present invention. Suitable compounds may include, for instance, proteinaceous compounds, such as insulin, immunoglobulins (e.g., IgG, IgM, IgA, IgE), TNF-α, antiviral medications, etc.; polynucleotide agents, such as plasmids, siRNA, RNAi, nucleoside anticancer drugs, vaccines, etc.; small molecule agents, such as alkaloids, glycosides, phenols, etc.; anti-infection agents, hormones, drugs regulating cardiac action or blood flow, pain control; and so forth. A non-limiting listing of agents includes anti-Angiogenesis agents, anti-depressants, antidiabetic agents, antihistamines, anti-inflammatory agents, butorphanol, calcitonin and analogs, COX-II inhibitors, dermatological agents, dopamine agonists and antagonists, enkephalins and other opioid peptides, epidermal growth factors, erythropoietin and analogs, follicle stimulating hormone, glucagon, growth hormone and analogs (including growth hormone releasing hormone), growth hormone antagonists, heparin, hirudin and hirudin analogs such as hirulog, IgE suppressors and other protein inhibitors, immunosuppressives, insulin, insulinotropin and analogs, interferons, interleukins, leutenizing hormone, leutenizing hormone releasing hormone and analogs, monoclonal or polyclonal antibodies, motion sickness preparations, muscle relaxants, narcotic analgesics, nicotine, non-steroid anti-inflammatory agents, oligosaccharides, parathyroid hormone and analogs, parathyroid hormone antagonists, prostaglandin antagonists, prostaglandins, scopolamine, sedatives, serotonin agonists and antagonists, sexual hypofunction, tissue plasminogen activators, tranquilizers, vaccines with or without carriers/adjuvants, vasodilators, major diagnostics such as tuberculin and other hypersensitivity agents as described in U.S. Pat. No. 6,569,143, which is incorporated herein by reference. Vaccine formulations may include an antigen or antigenic composition capable of eliciting an immune response against a human pathogen or from other viral pathogens.
- Due to its controlled capillary flow, the patch of the present invention may be particularly beneficial in delivering high molecular weight drug compounds that were previously difficult to deliver via transdermal delivery. The term “high molecular weight” generally refers to compounds having a molecular weight of about 1 kiliDalton (“kDa”) or more, in some embodiments about 10 kDa or more, in some embodiments about 20 kDa to about 250 kDa, and in some embodiments, from about greater than about 40 kDa to about 150 kDa. Examples of such high molecular weight compounds include protein therapeutics, which refers to any biologically active proteinaceous compound including, without limitation, natural, synthetic, and recombinant compounds, fusion proteins, chimeras, and so forth, as well as compounds including the 20 standard amino acids and/or synthetic amino acids. In one particular embodiment, the patch may be utilized in treatment of a chronic condition, such as rheumatoid arthritis (“RA”), to deliver a steady flow a drug to a subject in need thereof. RA drug compounds may include symptom suppression compounds, such as analgesics and anti-inflammatory drugs including both steroidal and non-steroidal anti-inflammatory drugs (NSAID), as well as disease-modifying antirheumatic drugs (“DMARD”). The patch can include and deliver symptom suppression compounds, such as analgesics and anti-inflammatory drugs, as well as DMARD compounds, including biological DMARDs. Through utilization of the transdermal patch of the present invention, RA drugs can be delivered at a steady concentration over a sustained period. The patch can prevent the initial burst of concentration common when utilizing previously known methods for delivery of RA drugs, including oral delivery and injection.
- RA drugs that may be incorporated in the patch can include, without limitation, one or more analgesics, anti-inflammatories, DMARDs, herbal-based drugs, and combinations thereof. Specific compounds can, of course, fall under one or more of the general categories described herein. For instance, many compounds function as both an analgesic and an anti-inflammatory; herbal-based drugs can likewise function as a DMARD as well as an anti-inflammatory. Moreover, multiple compounds that can fall under a single category can be incorporated in the patch. For instance, the patch can include multiple analgesics, such as acetaminophen with codeine, acetaminophen with hydrocodone (vicodin), and so forth. Examples of analgesics and/or NSAIDs include analgesics available over the counter (OTC) at relatively low dosages including acetamide (acetaminophen or paracetamol), acetylsalicylic acid (aspirin), ibuprofen, ketoprofen, naproxen and naproxen sodium, and so forth. Prescription analgesics and/or anti-inflammatories can include, without limitation, OTC analgesics at concentrations requiring a prescription, celecoxib, sulindac, oxaprozin, salsalate, piroxicam, indomethacin, etodolac, meloxicam, nabumetone, keteroloc and ketorolac tromethamine, tolmetin, diclofenac, diproqualone, and diflunisal. Narcotic analgesics can include codeine, hydrocodone, oxycodone, fentanyl, and propoxyphene.
- DMARDs can encompass both small molecule drugs and biological agents. DMARDs may be chemically synthesized or may be produced through genetic engineering processes (e.g., recombinant techniques). Chemically synthesized DMARDs encompassed herein include, without limitation, azathioprine, cyclosporine (ciclosporin, cyclosporine A), D-penicillamine, gold salts (e.g., auranofin, Na-aurothiomalate (Myocrism), chloroquine, hydroxychloroquine, leflunomide, methotrexate, minocycline, sulphasalazine (sulfasalazine), and cyclophosphamide. Biological DMARDs include, without limitation, TNF-α blockers such as etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), certolizamab pego (Cimzia®) and golumumab (Simponi™); IL-1 blockers such as anakinra (Kineret®); monoclonal antibodies against B cells including rituximab (Rituxan®); T cell costimulation blockers such as abatacept (Orencia®), and IL-6 blockers such as tocilizumab (RoActemra®, Actemra®); a calcineurin inhibitor such as tacrolimus (Prograf®). The patch may also incorporate multiple RA drugs. For instance, the patch can include a combination of DMARDs in addition to an analgesic and/or an anti-inflammatory drug. Common combinations of DMARDs include, for example, methotrexate in combination with hydroxychloroquine, methotrexate in combination with sulfasalazine, sulfasalazine in combination with hydroxychloroquine, and all three of these DMARDs together, i.e., hydroxychloroquine, methotrexate, and sulfasalazine.
- If desired, the patch may employ a plurality of reservoirs for storing multiple materials for delivery. The reservoirs may be positioned adjacent to each other, either in a vertical or horizontal relationship. For instance, a first reservoir may contain a drug compound and a second reservoir may contain an excipient (e.g., delivery vehicle, such as alcohols, water, etc.; buffering agents; and so forth). In one particular embodiment, for example, the first reservoir may contain a lyophilized powder of the drug compound (e.g., RA drug) and the second reservoir may contain an aqueous solution for reconstituting the powder. Alternatively, multiple reservoirs may be employed that each contains a drug compound. Regardless, the different materials may be mixed prior to delivery.
- B. Rate Control Membrane
- The drug delivery assembly also contains a rate control membrane that is in fluid communication with the drug reservoir. The rate control membrane can help slow down the flow rate of the drug compound upon its release. Specifically, fluidic drug compounds passing from the drug reservoir to the microneedle assembly may experience a drop in pressure that results in a reduction in flow rate. If this difference is too great, some backpressure may be created that can impede the flow of the compound and potentially overcome the capillary pressure of the fluid through the microfluidic channels. Thus, the use of the rate control membrane can ameliorate this difference in pressure and allow the drug compound to be introduced into the microneedle at a more controlled flow rate. The particular materials, thickness, etc. of the rate control membrane can vary based on multiple factors, such as the viscosity of the drug compound, the desired delivery time, etc.
- The rate-controlling membrane may be fabricated from permeable, semi-permeable or microporous materials that are known in the art to control the rate of drug compounds and having a permeability to the permeation enhancer lower than that of drug reservoir. For example, the material used to form the rate control membrane may have an average pore size of from about 50 nanometers to about 5 micrometers, in some embodiments from about 100 nanometers to about 2 micrometers, and in some embodiments, from about 300 nanometers to about 1 micrometer (e.g., about 600 nanometers). Suitable membrane materials include, for instance, fibrous webs (e.g., woven or nonwoven), apertured films, foams, sponges, etc., which are formed from polymers such as polyethylene, polypropylene, polyvinyl acetate, ethylene n-butyl acetate and ethylene vinyl acetate copolymers. Such membrane materials are also described in more detail in U.S. Pat. Nos. 3,797,494, 4,031,894, 4,201,211, 4,379,454, 4,436,741, 4,588,580, 4,615,699, 4,661,105, 4,681,584, 4,698,062, 4,725,272, 4,832,953, 4,908,027, 5,004,610, 5,310,559, 5,342,623, 5,344,656, 5,364,630, and 6,375,978, which are incorporated in their entirety herein by reference for all relevant purposes. A particularly suitable membrane material is available from Lohmann Therapie-Systeme.
- C. Other Layers
- If desired, the drug delivery assembly may contain additional layers or materials that provide various benefits to the resulting transdermal patch. In one embodiment, for example, the assembly includes an adhesive layer that can help facilitate the attachment of the patch to a user's skin during use. Although not required, the adhesive layer is often disposed over the reservoir. The adhesive layer typically employs an adhesive coated onto a backing material. The backing may be made of a material that is substantially impermeable to the drug compound, such as polymers, metal foils, etc. Suitable polymers may include, for instance, polyethylene terephthalate, polyvinylchloride, polyethylene, polypropylene, polycarbonate, polyester, and so forth. The adhesive may be a pressure-sensitive adhesive as is known in the art. Suitable adhesives may include, for instance, solvent-based acrylic adhesives, solvent-based rubber adhesives, silicone adhesives, etc.
- The transdermal patch of the present invention also contains a microneedle assembly that is capable of being placed in fluid communication with the drug delivery assembly described above. The microneedle assembly contains a plurality of microneedles that extend outwardly from a support. Referring to
FIGS. 13-14 , for example, one particular embodiment of amicroneedle assembly 310 is shown in more detail that contains a plurality ofmicroneedles 318 that extend from asupport 312. Thesupport 312 may be constructed from a rigid or flexible sheet of metal, ceramic, plastic or other material. Thesupport 312 can vary in thickness to meet the needs of the transdermal patch, such as about 1000 micrometers or less, in some embodiments from about 1 to about 500 micrometers, and in some embodiments, from about 10 to about 200 micrometers. Regardless of the manner in which it is constructed, anaperture 328 may be formed in thesupport 312 that extends through afirst surface 314 and a second opposingsurface 316. In the embodiment depicted inFIGS. 13 and 14 , themicroneedles 318 extend from thesecond surface 316, although in other embodiments themicroneedles 318 may extend from thefirst surface 314 or elsewhere. - It should be understood that the number of
microneedles 318 shown in the figures is for illustrative purposes only. The actual number of microneedles used in the patch may, for example, range from about 500 to about 10,000, in some embodiments from about 2,000 to about 8,000, and in some embodiments, from about 4,000 to about 6,000. The size and shape of themicroneedles 318 may also vary as desired. For example, themicroneedles 318 ofFIGS. 13 and 14 have an overall conical shape. In alternative embodiments, however, themicroneedles 318 may have an overall pyramidal shape or a cylindrical portion upon which is positioned a conical portion having a tip, such as is shown inFIGS. 17-18 . Regardless, themicroneedle 318 typically includes abase 320 and atip 322. As shown inFIG. 13 , thebase 320 is the portion of themicroneedle 318 that is proximate to thesecond surface 316 of thesupport 312. Thetip 322 of themicroneedle 318 is the point of themicroneedle 318 that is furthest from thebase 320. Although thetip 322 may be variously formed, it typically has a radius that is less than or equal to about 1 micrometer. Themicroneedles 318 are typically of a length sufficient to penetrate the stratum corneum and pass into the epidermis, but not penetrate through the epidermis and into the dermis in applications where it is desirable to minimize pain. In certain embodiments, the microneedles have a length (from theirtip 322 to their base 320) of about 500 micrometers or less, in some embodiments from 1 to about 400 micrometers, and in some embodiments, from about 50 to about 350 micrometers. - The
microneedles 318 may be arranged on the substrate in a variety of patterns, and such patterns may be designed for a particular use. For example, the microneedles may be spaced apart in a uniform manner, such as in a rectangular or square grid or in concentric circles. The spacing may depend on numerous factors, including height and width of themicroneedles 318, as well as the amount and type of substance that is intended to be moved through the microneedles. While a variety of arrangements of microneedles is useful in the present invention, a particularly useful arrangement ofmicroneedles 318 is a “tip-to-tip” spacing between microneedles of about 50 micrometers or more, in some embodiments about 100 to about 800 micrometers, and in some embodiments, from about 200 to about 600 micrometers. Themicroneedles 318 may be formed of various substances such as, for example, polymers, ceramics and metals. While numerous processes may be used to manufacture microneedles according to the present invention, a suitable production system is MEMS (Micro-Electro-Mechanical Systems) technology and microfabrication processes. MEMS is capable of forming micromechanical and other elements such as semiconductors on a single silicon substrate using microfabrication processes such as etching, micromachining or other processes. Thesupport 312 may be manufactured from silicon, the microneedles being subsequently formed by a microetching process. Micromolding techniques may also be used to form themicroneedles 318 andsupport 312. - Regardless of their particular configuration, the microneedles generally define at least one channel that is in fluidic communication with at least a portion of the aperture of the support. The dimensions of the channel are specifically selected in the present invention to induce capillary flow of the drug compound. Capillary flow generally occurs when the adhesive forces of a fluid to the walls of a channel are greater than the cohesive forces between the liquid molecules. Specifically, capillary pressure is inversely proportional to the cross-sectional dimension of the channel and directly proportional to the surface tension of the liquid, multiplied by the cosine of the contact angle of the fluid in contact with the material forming the channel. Thus, to facilitate capillary flow in the patch, the cross-sectional dimension (e.g., width, diameter, etc.) of the channel may be selectively controlled, with smaller dimensions generally resulting in higher capillary pressure. For example, in some embodiments, the cross-sectional dimension of the channel typically ranges from about 1 micrometer to about 100 micrometers, in some embodiments from about 5 micrometers to about 50 micrometers, and in some embodiments, from about 10 micrometers to about 30 micrometers. The dimension may be constant or it may vary as a function of the length of the channel. The length of the channel may also vary to accommodate different volumes, flow rates, and dwell times for the drug compound. For example, the length of the channel may be from about 10 micrometers to about 800 micrometers, in some embodiments from about 50 micrometers to about 500 micrometers, and in some embodiments, from about 100 micrometers to about 300 micrometers. The cross-sectional area of the channel may also vary. For example, the cross-sectional area may be from about 50 square micrometers to about 1,000 square micrometers, in some embodiments from about 100 square micrometers to about 500 square micrometers, and in some embodiments, from about 150 square micrometers to about 350 square micrometers. Further, the aspect ratio (length/cross-sectional dimension) of the channel may range from about 1 to about 50, in some embodiments from about 5 to about 40, and in some embodiments from about 10 to about 20. In cases where the cross-sectional dimension (e.g., width, diameter, etc.) and/or length vary as a function of length, the aspect ratio is determined from the average dimensions.
- Referring again to
FIGS. 13-14 , for example, the illustratedmicroneedles 318 contain at least onechannel 330. The channel may be located in a variety of different positions, such as in the interior of the channel, on an exterior surface, etc. In the embodiment illustrated inFIGS. 13-14 , for example, thechannel 330 is located on anexterior surface 324 of themicroneedle 318. The cross-section of thechannel 330, as shown inFIGS. 15-16 , is substantially U-shaped. Thechannel 330 may also be arcuate or have any other configuration suitable for moving a substance therethrough, such as, for example, V-shaped or C-shaped. Regardless, apathway 326 is formed by thechannel 330 and theaperture 328, which meet at ajunction 332 that is generally located in the plane of thesecond surface 316. Eachmicroneedle 318 may deliver or extract drug compounds through the skin via thepathway 326, as depicted inFIG. 14 . Thepathway 326 enables the compound to flow from thefirst surface 314 through theaperture 328, thejunction 332 and exiting into thechannel 330. By enabling the compound to flow through thesupport 312 and directly into thechannel 330, more precise control over the delivery location and the amount of substance delivered may be provided. - In certain embodiments and as shown in
FIG. 17 , anaperture 328 is aligned with asingle channel 330 via ajunction 332. Alternately and as shown in other figures, a single aperture may feed two or moreseparate channels 330. - The
channel 330 may extend from thejunction 332 at thebase 320 of the microneedle to thetip 322, as depicted inFIGS. 13 and 14 . In other embodiments, thechannel 330 may not extend the full length of themicroneedle 318 to thetip 322. Eachmicroneedle 318 may include more than onechannel 330, as seen in the embodiments ofFIGS. 17-19 . Alternate embodiments may include more channels if desired. Thechannel 330 may be variously positioned on theexterior surface 324, forming a substantially linear path from the base 320 towards thetip 322, or forming a winding or circuitous path along theexterior surface 324. In microneedles where two or more channels are present, thechannels 330 may be variously spaced around themicroneedle 318 in a symmetrical or asymmetrical manner. -
FIG. 16 is a view looking at thefirst surface 314 of themicroneedle assembly 310, which shows thejunction 332 that is formed in thepathway 326 by the overlapping portions of theaperture 328 and thechannel 330.FIG. 15 is a view looking down onto thesecond surface 316 of themicroneedle 318, showing thejunction 332 as seen from that portion of themicroneedle assembly 310, which may be in contact with the skin of a user. Thejunction 332 may vary in area betweenpathways 326 on a givenmicroneedle 318, and may vary betweenmicroneedles 318 on a givenmicroneedle assembly 310. The area of thejunction 332 may vary widely, and will depend on factors such as, for example, the diameter of themicroneedle 318, the viscosity of the substance to be moved through thepathway 326 and the quantity of substance to be delivered. In certain embodiments, the area of thejunction 332 at thesecond surface 316 is greater than or equal to about 100 square microns, although smaller areas may also be acceptable for use in the present invention. In other embodiments, the area of thejunction 332 at thesecond surface 316 may be equal to about 150 square microns or greater. -
FIG. 17 illustrates embodiments of themicroneedle 318 in which theaperture 328 andchannel 330 have sides that are not only coextensive with each other but may also be planar for at least some distance along the length of thepathway 326.FIGS. 18-19 illustrate an embodiment where asingle aperture 328 is aligned with more than onechannel 330 on aparticular microneedle 318.FIG. 20 is a view of thesecond surface 316 of themicroneedle assembly 310 shown inFIG. 19 , illustrating the alignment of themicroneedle 318, thechannels 330, theaperture 328 and thejunctions 332. - As indicated above, a release member is initially positioned adjacent to the microneedle assembly and the drug delivery assembly so that it is adjacent to the support of the microneedle assembly and the rate control membrane of the drug delivery assembly. It should be understood, however, that the release layer need not contact such layers, and that other layers may be in fact be positioned between the release member and the support and/or rate control membrane. Regardless, the release member is made of a material that is substantially impermeable to the drug compound, such as a polymeric material, metal, etc. The material is also desirably hydrophobic. Suitable polymeric materials may include, for instance, polyethylene terephthalate, polyvinylchloride, polyethylene, polypropylene, polycarbonate, polyester, metal foils, and so forth. Because it is generally impermeable, the release member can initially seal the aperture in the support and thus limit the flow of the drug compound therethrough. When it is desired to use the patch, a force may be applied by the user to at least partially separate the release member, thereby breaking the seal.
- The separation of the release member may be accomplished in a variety of ways. For instance, a portion of the release member may simply be ruptured. Any of a variety of known techniques for forming a rupturable layer may be employed in the present invention. In one embodiment, for example, the release member may be bonded about its perimeter. The strength of the bonds may exceed the tensile strength of the release member so that when a tensile force is applied, an inner portion of the substrate ruptures while the bonded perimeter remains in tact.
- In alternative embodiments, separation may be accomplished through the partial or complete detachment of the release member. For example, referring to
FIGS. 1-6 , one embodiment of a release member is shown that is configured to be detached from the transdermal patch to initiate the flow of the drug compound. More particularly,FIGS. 1-2 show atransdermal patch 100 that contains adrug delivery assembly 170 and amicroneedle assembly 180. Thedrug delivery assembly 170 includes areservoir 106 positioned adjacent to arate control membrane 108, such as described above. Although optional, theassembly 170 also contains anadhesive layer 104 that is positioned adjacent to thereservoir 106. Themicroneedle assembly 180 likewise includes asupport 112 from which extends a plurality ofmicroneedles 130 havingchannels 131, such as described above. The layers of thedrug delivery assembly 170 and/or themicroneedle assembly 180 may be attached together if desired using any known bonding technique, such as through adhesive bonding, thermal bonding, ultrasonic bonding, etc. - Regardless of the particular configuration employed, the
patch 100 also contains arelease member 110 that is positioned between thedrug delivery assembly 170 and themicroneedle assembly 180. While therelease member 110 may optionally be bonded to theadjacent support 112 and/orrate control membrane 108, it is typically desired that it is only lightly bonded, if at all, so that therelease member 110 can be easily withdrawn from thepatch 100. If desired, therelease member 110 may also contain a tab portion 171 (FIGS. 1-2 ) that extends at least partly beyond the perimeter of thepatch 100 to facilitate the ability of a user to grab onto the member and pull it in the desired direction. In its “inactive” configuration as shown inFIGS. 1-2 , thedrug delivery assembly 170 of thepatch 100 securely retains adrug compound 107 so that it does not flow to any significant extent into themicroneedles 130. As indicated above, the patch can be “activated” by simply applying a force to the release member so that it is detached from the patch. Referring toFIGS. 3-4 , one embodiment for activating thepatch 100 is shown in which therelease member 110 is pulled in a longitudinal direction. Theentire release member 110 may be removed as shown inFIGS. 5-6 , or it may simply be partially detached as shown inFIGS. 3-4 . In either case, however, the seal previously formed between therelease member 110 and the aperture (not shown) of thesupport 112 is broken. In this manner, adrug compound 107 can begin to flow from thedrug delivery assembly 170 and into thechannels 131 of themicroneedles 130 via thesupport 112. An exemplary illustration of how thedrug compound 107 flows from thereservoir 106 and into thechannels 131 is shown inFIGS. 5-6 . Notably, the flow of thedrug compound 107 is passively initiated and does not require any active displacement mechanisms (e.g., pumps). - In the embodiments shown in
FIGS. 1-6 and discussed above, the detachment of the release member immediately initiates the flow of the drug compound to the microneedles because the drug delivery assembly is already disposed in fluid communication with the microneedle assembly. In certain embodiments, however, it may be desired to provide the user with a greater degree of control over the timing of the release of the drug compound. This may be accomplished by using a patch configuration in which the microneedle assembly is not initially in fluid communication with the drug delivery assembly. When it is desired to use the patch, the user may physically manipulate the two separate assemblies into fluid communication. The release member may be separated either before or after such physical manipulation occurs. - Referring to
FIGS. 7-12 , for example, one particular embodiment of apatch 200 is shown.FIGS. 7-8 illustrate thepatch 200 before use, and shows afirst section 250 formed by amicroneedle assembly 280 and asecond section 260 formed by adrug delivery assembly 270. Thedrug delivery assembly 270 includes areservoir 206 positioned adjacent to arate control membrane 208 as described above. Although optional, theassembly 270 also contains anadhesive layer 204 that is positioned adjacent to thereservoir 206. Themicroneedle assembly 280 likewise includes asupport 212 from which extends a plurality ofmicroneedles 230 havingchannels 231, such as described above. - In this embodiment, the
support 212 and therate control membrane 208 are initially positioned horizontally adjacent to each other, and arelease member 210 extends over thesupport 212 and therate control member 208. In this particular embodiment, it is generally desired that therelease member 210 releasably attached to thesupport 212 and therate control membrane 208 with an adhesive (e.g., pressure-sensitive adhesive). In its “inactive” configuration as shown inFIGS. 7-8 , thedrug delivery assembly 270 of thepatch 200 securely retains adrug compound 207 so that it does not flow to any significant extent into themicroneedles 230. When it is desired to “activate” the patch, therelease member 210 may be peeled away and removed, such as illustrated inFIGS. 9-10 , to break the seal previously formed between therelease member 210 and the aperture (not shown) of thesupport 212. Thereafter, thesecond section 260 may be folded about a fold line “F” as shown by the directional arrow inFIG. 11 so that therate control member 208 is positioned vertically adjacent to thesupport 212 and in fluid communication therewith. Alternatively, thefirst section 250 may be folded. Regardless, folding of thesections 250 and/or 260 initiates the flow of adrug compound 207 from thedrug delivery assembly 270 and into thechannels 231 of themicroneedles 230 via the support 212 (SeeFIG. 12 ). - The embodiments illustrated above contain only a single release member. However, it should be understood that additional release members may be employed in the present invention to accomplish a variety of different purposes. Referring to
FIG. 21 , for example, one particular embodiment of apatch 400 is shown that employs adrug delivery assembly 470 and amicroneedle assembly 480. In this embodiment, thedrug delivery assembly 470 includes twoseparate reservoirs second reservoir 406 b may, for example, contain a powdered drug compound 407 (e.g., RA drug) and thefirst reservoir 406 a may contain a liquid solution (not shown) for reconstituting the powder. Initially, the solution and drug compound remain separate to enhance the long term stability of the drug compound. Prior to use, however, afirst release member 410 b may be separated from thereservoirs FIG. 21 . In any event, separation of thefirst release member 410 b causes the ingredients in the reservoirs to mix together to form a solution form of the drug compound. Thereafter, asecond release member 410 a may likewise be separated from arate control membrane 408 and asupport 412 of themicroneedle assembly 480. This causes the drug compound to flow from therate control membrane 408 intochannels 431 of themicroneedles 430. Although optional, thepatch 400 may also contain anadhesive layer 404 to help adhere it to the skin of a user. - Regardless of the particular manner in which it is employed, the present inventors have discovered that the release member can provide a variety of different benefits to the resulting transdermal patch. For instance, because the release member is easily separated, flow of the drug compound may be initiated by a user without necessarily requiring the aid of a medical professional. Furthermore, because it is configured for separation, the extent to which the release member is bonded to adjacent layers is generally minimized, if at all. Such a lightly bonded release member may leave a small space between the layers to which it is adjacent when it is separated (partially or completely) therefrom. Notably, the present inventors have discovered that this small space may form a microreservoir that temporarily holds the drug compound before it enters the microneedle assembly. Among other things, this microreservoir is believed to further assist in the capillary flow through the channels of the microneedles. Just as an example, one embodiment of such a microreservoir is shown in more detail in
FIGS. 5-6 aselement 190. Although it may vary, the thickness of themicroreservoir 190 is typically from about 50 nanometers to about 50 micrometers, in some embodiments from about 100 nanometers to about 10 micrometers, and in some embodiments, from about 200 nanometers to about 1 micrometer. - While the invention has been described in detail with respect to the specific embodiments thereof, it will be appreciated that those skilled in the art, upon attaining an understanding of the foregoing, may readily conceive of alterations to, variations of, and equivalents to these embodiments. In addition, it should be noted that any given range presented herein is intended to include any and all lesser included ranges. For example, a range of from 45-90 would also include 50-90; 45-80; 46-89 and so forth. Accordingly, the scope of the present invention should be assessed as that of the appended claims and any equivalents thereto.
Claims (30)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/036,096 US8696637B2 (en) | 2011-02-28 | 2011-02-28 | Transdermal patch containing microneedles |
MX2013009591A MX2013009591A (en) | 2011-02-28 | 2012-01-16 | Transdermal patch containing microneedles. |
BR112013021282A BR112013021282A2 (en) | 2011-02-28 | 2012-01-16 | transdermal patch and method for transdermally delivering a drug compound |
EP12752358.7A EP2680918A4 (en) | 2011-02-28 | 2012-01-16 | Transdermal patch containing microneedles |
AU2012222971A AU2012222971B2 (en) | 2011-02-28 | 2012-01-16 | Transdermal patch containing microneedles |
CN2012800103632A CN103384545A (en) | 2011-02-28 | 2012-01-16 | Transdermal patch containing microneedles |
RU2013141508/14A RU2013141508A (en) | 2011-02-28 | 2012-01-16 | MICRO NEEDLE TRANSDERMAL PLASTER |
CA2825591A CA2825591A1 (en) | 2011-02-28 | 2012-01-16 | Transdermal patch containing microneedles |
KR1020137022125A KR20140006903A (en) | 2011-02-28 | 2012-01-16 | Transdermal patch containing microneedles |
PCT/IB2012/050203 WO2012117302A2 (en) | 2011-02-28 | 2012-01-16 | Transdermal patch containing microneedles |
JP2013555950A JP2014511243A (en) | 2011-02-28 | 2012-01-16 | Transdermal patch with microneedle |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/036,096 US8696637B2 (en) | 2011-02-28 | 2011-02-28 | Transdermal patch containing microneedles |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120220980A1 true US20120220980A1 (en) | 2012-08-30 |
US8696637B2 US8696637B2 (en) | 2014-04-15 |
Family
ID=46719489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/036,096 Active 2032-05-30 US8696637B2 (en) | 2011-02-28 | 2011-02-28 | Transdermal patch containing microneedles |
Country Status (11)
Country | Link |
---|---|
US (1) | US8696637B2 (en) |
EP (1) | EP2680918A4 (en) |
JP (1) | JP2014511243A (en) |
KR (1) | KR20140006903A (en) |
CN (1) | CN103384545A (en) |
AU (1) | AU2012222971B2 (en) |
BR (1) | BR112013021282A2 (en) |
CA (1) | CA2825591A1 (en) |
MX (1) | MX2013009591A (en) |
RU (1) | RU2013141508A (en) |
WO (1) | WO2012117302A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8636696B2 (en) | 2011-06-10 | 2014-01-28 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
WO2014142749A1 (en) * | 2013-03-15 | 2014-09-18 | National University Of Singapore | Microneedles integrated with nanotubes |
US20150174386A1 (en) * | 2013-12-19 | 2015-06-25 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
EP2918263A1 (en) * | 2014-03-13 | 2015-09-16 | Sabanci Üniversitesi | Pharmaceutical drug delivery system |
WO2017189259A2 (en) | 2016-04-29 | 2017-11-02 | Kimberly-Clark Worldwide, Inc. | Microneedle array assembly and fluid delivery apparatus having such an assembly |
CN109475726A (en) * | 2016-04-29 | 2019-03-15 | 索伦托治疗有限公司 | Microneedle array package, drug delivery device and the method for large area low pressure infusion liquid |
WO2019069102A1 (en) * | 2017-10-06 | 2019-04-11 | Xobaderm Limited | Kit for delivery of an active compound into the skin |
WO2019194871A1 (en) * | 2018-04-05 | 2019-10-10 | Erbst Steven Robert | Therapeutic elastic bandage for modulating the endocannabinoid system |
WO2020003248A1 (en) * | 2018-06-29 | 2020-01-02 | Johnson & Johnson Consumer Inc. | Three-dimensional microfluidics devices for the delivery of actives |
US10869842B1 (en) * | 2016-09-07 | 2020-12-22 | David P Summers | Transdermal delivery of pharmaceutical agents |
WO2021003315A1 (en) * | 2019-07-02 | 2021-01-07 | Rowley Clifford T | Transdermal patch providing improved permeability |
US11241563B2 (en) | 2016-12-22 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Microneedle arrays and methods for making and using |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8834423B2 (en) | 2009-10-23 | 2014-09-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Dissolvable microneedle arrays for transdermal delivery to human skin |
WO2012046149A1 (en) | 2010-04-28 | 2012-04-12 | Kimberly-Clark Worldwide, Inc. | Method for increasing permeability of an epithelial barrier |
EP2563451B1 (en) | 2010-04-28 | 2017-11-01 | Kimberly-Clark Worldwide, Inc. | MEDICAL DEVICES FOR DELIVERY OF siRNA |
CN102958555A (en) | 2010-04-28 | 2013-03-06 | 金伯利-克拉克环球有限公司 | Injection molded microneedle array and method for forming the microneedle array |
JP5860032B2 (en) | 2010-04-28 | 2016-02-16 | キンバリー クラーク ワールドワイド インコーポレイテッド | Device for the delivery of rheumatoid arthritis drugs |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2862955T3 (en) | 2010-10-01 | 2021-10-08 | Modernatx Inc | Manipulated nucleic acids and methods of using them |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2013052523A1 (en) | 2011-10-03 | 2013-04-11 | modeRNA Therapeutics | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
KR20220051429A (en) | 2011-10-27 | 2022-04-26 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Transdermal delivery of high viscosity bioactive agents |
ES2908653T3 (en) | 2011-10-27 | 2022-05-03 | Sorrento Therapeutics Inc | Implantable devices for the administration of bioactive agents |
US20170246439A9 (en) | 2011-10-27 | 2017-08-31 | Kimberly-Clark Worldwide, Inc. | Increased Bioavailability of Transdermally Delivered Agents |
CN104114572A (en) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP2833920A2 (en) | 2012-04-02 | 2015-02-11 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
WO2013166162A1 (en) | 2012-05-01 | 2013-11-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Tip-loaded microneedle arrays for transdermal insertion |
PL2922554T3 (en) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Terminally modified rna |
CN103505806B (en) * | 2012-12-27 | 2016-04-06 | 中国人民解放军第二军医大学 | electret nanoparticle transdermal drug delivery system |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN103550191A (en) * | 2013-10-15 | 2014-02-05 | 温天文 | Ibuprofen and its salt painless microneedle transdermal patch and its preparation method |
CA3163792A1 (en) * | 2014-04-24 | 2015-10-29 | Georgia Tech Research Corporation | Microneedles and methods of manufacture thereof |
US9138191B1 (en) * | 2014-07-09 | 2015-09-22 | Qualcomm Incorporated | Integrated circuit module with lead frame micro-needles |
US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
WO2016149673A1 (en) | 2015-03-18 | 2016-09-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
KR102139336B1 (en) * | 2015-04-20 | 2020-07-29 | 주식회사 엘지생활건강 | Soluble Microneedle device having improved absorbing rate of active agent and kit comprising thereof |
US11684763B2 (en) | 2015-10-16 | 2023-06-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices |
US20180369136A1 (en) * | 2015-12-28 | 2018-12-27 | North Carolina State University | Devices and methods for transdermal treatment of basal cell carcinoma |
US10518071B2 (en) | 2015-12-29 | 2019-12-31 | Gajanan Kulkarni | Transdermal microneedle drug delivery device and method |
WO2017120322A1 (en) | 2016-01-05 | 2017-07-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Skin microenvironment targeted delivery for promoting immune and other responses |
US10493049B2 (en) | 2016-02-10 | 2019-12-03 | Niracle LLC | Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations |
BR112019012924A2 (en) * | 2016-12-22 | 2019-12-10 | Ohio State Innovation Foundation | nanochannel-based interpenetrating charge-release microstructures |
EP3564672A4 (en) * | 2016-12-28 | 2020-09-09 | Nexmos Co., Ltd. | Method for fabricating microneedle-based diagnostic skin patch coated with aptamer and patch |
US20200268681A1 (en) | 2016-12-29 | 2020-08-27 | International Bioceutical Co. LLC | Modular transdermal delivery system and associated methods of manufacture and use |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
CN107007927A (en) * | 2017-02-21 | 2017-08-04 | 中山大学 | A kind of microneedle array drug paste and preparation method being administered based on electric field driven |
TW201840307A (en) | 2017-03-24 | 2018-11-16 | 美商伊英克加利福尼亞有限責任公司 | Microcell systems for delivering active molecules |
JP6832456B2 (en) | 2017-03-24 | 2021-02-24 | イー インク カリフォルニア, エルエルシー | Microcell delivery system containing charged or magnetic particles for adjusting the dosing rate of active molecules |
EP3603731A4 (en) * | 2017-03-31 | 2020-07-15 | Toppan Printing Co., Ltd. | Percutaneous administration device |
US9901545B1 (en) | 2017-04-13 | 2018-02-27 | Richard C. Fuisz | Method and composition for making an oral soluble film, containing at least one active agent |
US10238600B2 (en) | 2017-04-13 | 2019-03-26 | Richard C. Fuisz | Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent |
USD851760S1 (en) * | 2017-06-05 | 2019-06-18 | Bomtech Electronics Co., Ltd. | Needle unit for automatic injecting device |
JP1601442S (en) * | 2017-07-28 | 2018-04-09 | ||
GB2568287A (en) * | 2017-11-10 | 2019-05-15 | Sisaf Ltd | Apparatus and methods for the transdermal delivery of active agents |
WO2019099320A1 (en) | 2017-11-14 | 2019-05-23 | E Ink California, Llc | Electrophoretic active delivery system including porous conductive electrode layer |
US11318292B2 (en) * | 2018-05-28 | 2022-05-03 | Microneedles Inc. | Microneedle patch for transdermal injections |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
CN109528695B (en) * | 2019-01-12 | 2022-04-19 | 蚌埠医学院 | Microneedle transdermal drug delivery patch for treating rheumatoid arthritis and preparation method thereof |
CN110270006B (en) * | 2019-07-11 | 2022-03-01 | 上海揽微医学科技有限公司 | Prismatic metal microneedle and preparation method thereof |
EP3795358A1 (en) * | 2019-09-20 | 2021-03-24 | Axenoll Life Sciences AG | Microneedle and method for manufacturing same |
EP4065209A4 (en) | 2019-11-27 | 2023-11-29 | E Ink California, LLC | Benefit agent delivery system comprising microcells having an electrically eroding sealing layer |
USD910842S1 (en) * | 2020-05-14 | 2021-02-16 | Gravity Holdings, LLC | Square shaped hypodermic needle array with evenly spaced needles |
USD921194S1 (en) * | 2020-05-14 | 2021-06-01 | Gravity Holdings, LLC | Triangular hypodermic needle array |
USD920505S1 (en) * | 2020-05-14 | 2021-05-25 | Gravity Holdings, LLC | Square shaped hypodermic needle array |
USD920506S1 (en) * | 2020-05-14 | 2021-05-25 | Gravity Holdings, LLC | Rectangular hypodermic needle array |
USD921193S1 (en) * | 2020-05-14 | 2021-06-01 | Gravity Holdings, LLC | Circular hypodermic needle array |
USD910841S1 (en) * | 2020-05-14 | 2021-02-16 | Gravity Holdings, LLC | Circular hypodermic needle array with evenly spaced needles |
USD910844S1 (en) * | 2020-05-14 | 2021-02-16 | Gravity Holdings, LLC | Rectangular hypodermic needle array with evenly spaced needles |
USD910843S1 (en) * | 2020-05-14 | 2021-02-16 | Gravity Holdings, LLC | Triangular hypodermic needle array with evenly spaced needles |
JP1687031S (en) * | 2020-06-30 | 2021-06-07 | ||
EP4236927A1 (en) | 2020-10-29 | 2023-09-06 | E Ink California, LLC | Microcell systems for delivering hydrophilic active molecules |
EP4236926A1 (en) | 2020-10-29 | 2023-09-06 | E Ink California, LLC | Microcell systems for delivering benefit agents |
CN112999505A (en) * | 2021-03-16 | 2021-06-22 | 苏州肌之究极医药科技有限公司 | Microneedle transdermal delivery system |
US11369789B2 (en) | 2021-04-05 | 2022-06-28 | Ishaan Jain | Transdermal drug delivery system |
US20220330860A1 (en) | 2021-04-14 | 2022-10-20 | Neoenta LLC | Dermal patch system |
CN113712547B (en) * | 2021-09-07 | 2023-12-29 | 集美大学 | Multi-groove microneedle array, preparation method thereof and biological detection microneedle sensor |
US11877848B2 (en) | 2021-11-08 | 2024-01-23 | Satio, Inc. | Dermal patch for collecting a physiological sample |
EP4308088A1 (en) | 2021-11-08 | 2024-01-24 | Weiyong Li | Transdermal drug delivery system for delivering a drug to a patient |
US11510602B1 (en) | 2021-11-08 | 2022-11-29 | Satio, Inc. | Dermal patch for collecting a physiological sample |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US4167179A (en) * | 1977-10-17 | 1979-09-11 | Mark Kirsch | Planar radioactive seed implanter |
US20050177106A1 (en) * | 2001-10-15 | 2005-08-11 | Scimed Life Systems, Inc. | Medical device for delivering patches |
US20050181033A1 (en) * | 2000-06-29 | 2005-08-18 | Dekker John P.Iii | Method for delivering interferons to the intradermal compartment |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US4436741A (en) | 1975-12-08 | 1984-03-13 | Alza Corporation | Method for administering scopolamine transdermally |
US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4725272A (en) | 1981-06-29 | 1988-02-16 | Alza Corporation | Novel bandage for administering beneficial drug |
US4661105A (en) | 1981-06-29 | 1987-04-28 | Alza Corporation | Medical bandage for administering vasodilator drug |
US5310559A (en) | 1982-09-01 | 1994-05-10 | Hercon Laboratories Corporation | Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer |
US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
US4681584A (en) | 1985-05-03 | 1987-07-21 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
US4615699A (en) | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
US4698062A (en) | 1985-10-30 | 1987-10-06 | Alza Corporation | Medical device for pulsatile transdermal delivery of biologically active agents |
US4627429A (en) * | 1986-02-28 | 1986-12-09 | American Home Products Corporation | Storage-stable transdermal adhesive patch |
US4880633A (en) | 1986-03-12 | 1989-11-14 | Merck & Co., Inc. | Transdermal drug delivery system |
US5344656A (en) | 1986-09-12 | 1994-09-06 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4908027A (en) | 1986-09-12 | 1990-03-13 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4832953A (en) | 1987-08-13 | 1989-05-23 | Alza Corporation | Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix |
US5364630A (en) | 1988-06-14 | 1994-11-15 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
US5004610A (en) | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
DE3903794A1 (en) * | 1989-02-09 | 1990-08-16 | Lohmann Therapie Syst Lts | THERAPEUTIC SYSTEM FOR THE TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE SUBSTANCES AND ITS USE |
DE19525607A1 (en) | 1995-07-14 | 1997-01-16 | Boehringer Ingelheim Kg | Transcorneal drug delivery system |
JPH09201420A (en) * | 1996-01-30 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | Device for iontophoresis being active on use |
WO1998028037A1 (en) * | 1996-12-20 | 1998-07-02 | Alza Corporation | Device and method for enhancing transdermal agent flux |
JP4215188B2 (en) | 1997-12-22 | 2009-01-28 | インターシア セラピューティクス,インコーポレイティド | Rate-regulating membranes for devices that regulate drug delivery |
US7048723B1 (en) | 1998-09-18 | 2006-05-23 | The University Of Utah Research Foundation | Surface micromachined microneedles |
US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
IL134997A0 (en) | 2000-03-09 | 2001-05-20 | Yehoshua Yeshurun | Health care system based on micro device |
US6440096B1 (en) | 2000-07-14 | 2002-08-27 | Becton, Dickinson And Co. | Microdevice and method of manufacturing a microdevice |
US6656147B1 (en) | 2000-07-17 | 2003-12-02 | Becton, Dickinson And Company | Method and delivery device for the transdermal administration of a substance |
US7108681B2 (en) | 2000-10-16 | 2006-09-19 | Corium International, Inc. | Microstructures for delivering a composition cutaneously to skin |
US7131987B2 (en) | 2000-10-16 | 2006-11-07 | Corium International, Inc. | Microstructures and method for treating and conditioning skin which cause less irritation during exfoliation |
US6591124B2 (en) | 2001-05-11 | 2003-07-08 | The Procter & Gamble Company | Portable interstitial fluid monitoring system |
US6767341B2 (en) | 2001-06-13 | 2004-07-27 | Abbott Laboratories | Microneedles for minimally invasive drug delivery |
SE0102736D0 (en) | 2001-08-14 | 2001-08-14 | Patrick Griss | Side opened out-of-plane microneedles for microfluidic transdermal interfacing and fabrication process of side opened out-of-plane microneedles |
US6881203B2 (en) | 2001-09-05 | 2005-04-19 | 3M Innovative Properties Company | Microneedle arrays and methods of manufacturing the same |
AU2002333554C1 (en) | 2001-09-12 | 2008-12-11 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
US20040087992A1 (en) | 2002-08-09 | 2004-05-06 | Vladimir Gartstein | Microstructures for delivering a composition cutaneously to skin using rotatable structures |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
WO2003074102A2 (en) | 2002-03-04 | 2003-09-12 | Nano Pass Technologies Ltd. | Devices and methods for transporting fluid across a biological barrier |
US7115108B2 (en) | 2002-04-02 | 2006-10-03 | Becton, Dickinson And Company | Method and device for intradermally delivering a substance |
CN100479875C (en) | 2002-07-22 | 2009-04-22 | 贝克顿·迪金森公司 | Patch-like infusion device |
WO2004033021A1 (en) | 2002-10-07 | 2004-04-22 | Biovalve Technologies, Inc. | Microneedle array patch |
US7578954B2 (en) | 2003-02-24 | 2009-08-25 | Corium International, Inc. | Method for manufacturing microstructures having multiple microelements with through-holes |
US20040260234A1 (en) | 2003-04-21 | 2004-12-23 | Ravi Srinivasan | Apparatus and methods for repetitive microjet durg delivery priority statement |
US7753888B2 (en) | 2003-11-21 | 2010-07-13 | The Regents Of The University Of California | Method and/or apparatus for puncturing a surface for extraction, in situ analysis, and/or substance delivery using microneedles |
JP4832082B2 (en) | 2004-02-03 | 2011-12-07 | 久光製薬株式会社 | Interface for transdermal drug delivery device |
US8551391B2 (en) | 2004-02-17 | 2013-10-08 | Avery Dennison Corporation | Method of making microneedles |
WO2005094526A2 (en) | 2004-03-24 | 2005-10-13 | Corium International, Inc. | Transdermal delivery device |
US7315758B2 (en) | 2004-06-03 | 2008-01-01 | Lynntech, Inc. | Transdermal delivery of therapeutic agent |
WO2006015299A2 (en) | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
WO2006016364A2 (en) | 2004-08-10 | 2006-02-16 | Hellman De Picciotto, Tania | Drug delivery devices |
US20070250018A1 (en) | 2004-08-12 | 2007-10-25 | Hirotoshi Adachi | Transdermal Drug Administration System with Microneedles |
US7316665B2 (en) | 2004-08-25 | 2008-01-08 | Becton, Dickinson And Company | Method and device for the delivery of a substance including a covering |
US7627938B2 (en) | 2004-10-15 | 2009-12-08 | Board Of Regents, The Univeristy Of Texas System | Tapered hollow metallic microneedle array assembly and method of making and using the same |
EP1819379B1 (en) | 2004-11-18 | 2016-08-31 | Nanopass Technologies Ltd. | System for delivering fluid into flexible biological barrier |
WO2006055799A1 (en) | 2004-11-18 | 2006-05-26 | 3M Innovative Properties Company | Masking method for coating a microneedle array |
CA2589733C (en) | 2004-12-07 | 2014-02-11 | 3M Innovative Properties Company | Method of molding a microneedle |
WO2007002523A2 (en) | 2005-06-24 | 2007-01-04 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
JP2008543528A (en) | 2005-06-27 | 2008-12-04 | スリーエム イノベイティブ プロパティズ カンパニー | Microneedle cartridge assembly and application method |
US7658728B2 (en) | 2006-01-10 | 2010-02-09 | Yuzhakov Vadim V | Microneedle array, patch, and applicator for transdermal drug delivery |
WO2007091608A1 (en) | 2006-02-10 | 2007-08-16 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal drug administration apparatus having microneedles |
WO2007116959A1 (en) | 2006-04-07 | 2007-10-18 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device and transdermal administration device provided with microneedles |
CN1830496A (en) | 2006-04-10 | 2006-09-13 | 清华大学 | '-'-shaped structure three-dimensional micre solid, hollow silicone meedle orknife |
US9119945B2 (en) | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
US7918814B2 (en) | 2006-05-02 | 2011-04-05 | Georgia Tech Research Corporation | Method for drug delivery to ocular tissue using microneedle |
US20070276318A1 (en) | 2006-05-26 | 2007-11-29 | Mit, Llp | Iontosonic-microneedle applicator apparatus and methods |
EP2043728A2 (en) | 2006-07-11 | 2009-04-08 | Microchips, Inc. | Multi-reservoir pump device for dialysis, biosensing, or delivery of substances |
US20080091226A1 (en) | 2006-10-17 | 2008-04-17 | Nanopass Technologies Ltd. | Microneedle device |
US7785301B2 (en) | 2006-11-28 | 2010-08-31 | Vadim V Yuzhakov | Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection |
EP2146689B1 (en) | 2007-04-16 | 2020-08-12 | Corium, Inc. | Solvent-cast microneedle arrays containing active |
US20100121307A1 (en) | 2007-08-24 | 2010-05-13 | Microfabrica Inc. | Microneedles, Microneedle Arrays, Methods for Making, and Transdermal and/or Intradermal Applications |
US20090099427A1 (en) | 2007-10-12 | 2009-04-16 | Arkal Medical, Inc. | Microneedle array with diverse needle configurations |
CA2745339C (en) | 2007-12-24 | 2016-06-28 | The University Of Queensland | Coating method |
JP5476062B2 (en) * | 2008-07-25 | 2014-04-23 | 南部化成株式会社 | Transdermal device |
KR101039078B1 (en) | 2009-08-04 | 2011-06-07 | (주)마이티시스템 | Effective component delivery system having micro-needle and movable storage capsule |
US20110021996A1 (en) | 2008-12-18 | 2011-01-27 | Miti Systems Inc. | Structure of micro-needle with side channel and manufacturing method thereof |
WO2010070628A1 (en) | 2008-12-19 | 2010-06-24 | Janisys Limited | A fluid transfer device and an active substance cartridge for the fluid transfer device, and a method for controlling the pressure at which an active substance is delivered to a subject from a fluid transfer device |
KR101033513B1 (en) | 2009-01-20 | 2011-05-09 | (주)마이티시스템 | Case for the effective component delivery using micro-needle |
JP5558047B2 (en) * | 2009-08-13 | 2014-07-23 | 深江化成株式会社 | Substance supply device |
US20110144591A1 (en) | 2009-12-11 | 2011-06-16 | Ross Russell F | Transdermal Delivery Device |
CN102958555A (en) | 2010-04-28 | 2013-03-06 | 金伯利-克拉克环球有限公司 | Injection molded microneedle array and method for forming the microneedle array |
JP5860032B2 (en) | 2010-04-28 | 2016-02-16 | キンバリー クラーク ワールドワイド インコーポレイテッド | Device for the delivery of rheumatoid arthritis drugs |
WO2012046149A1 (en) | 2010-04-28 | 2012-04-12 | Kimberly-Clark Worldwide, Inc. | Method for increasing permeability of an epithelial barrier |
EP2563451B1 (en) | 2010-04-28 | 2017-11-01 | Kimberly-Clark Worldwide, Inc. | MEDICAL DEVICES FOR DELIVERY OF siRNA |
-
2011
- 2011-02-28 US US13/036,096 patent/US8696637B2/en active Active
-
2012
- 2012-01-16 WO PCT/IB2012/050203 patent/WO2012117302A2/en active Application Filing
- 2012-01-16 JP JP2013555950A patent/JP2014511243A/en active Pending
- 2012-01-16 CN CN2012800103632A patent/CN103384545A/en active Pending
- 2012-01-16 MX MX2013009591A patent/MX2013009591A/en not_active Application Discontinuation
- 2012-01-16 BR BR112013021282A patent/BR112013021282A2/en not_active IP Right Cessation
- 2012-01-16 AU AU2012222971A patent/AU2012222971B2/en not_active Expired - Fee Related
- 2012-01-16 CA CA2825591A patent/CA2825591A1/en not_active Abandoned
- 2012-01-16 EP EP12752358.7A patent/EP2680918A4/en not_active Withdrawn
- 2012-01-16 RU RU2013141508/14A patent/RU2013141508A/en not_active Application Discontinuation
- 2012-01-16 KR KR1020137022125A patent/KR20140006903A/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US4167179A (en) * | 1977-10-17 | 1979-09-11 | Mark Kirsch | Planar radioactive seed implanter |
US20050181033A1 (en) * | 2000-06-29 | 2005-08-18 | Dekker John P.Iii | Method for delivering interferons to the intradermal compartment |
US20050177106A1 (en) * | 2001-10-15 | 2005-08-11 | Scimed Life Systems, Inc. | Medical device for delivering patches |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8636696B2 (en) | 2011-06-10 | 2014-01-28 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
WO2014142749A1 (en) * | 2013-03-15 | 2014-09-18 | National University Of Singapore | Microneedles integrated with nanotubes |
US20150174386A1 (en) * | 2013-12-19 | 2015-06-25 | Kimberly-Clark Worldwide, Inc. | Transdermal device containing microneedles |
WO2015136036A1 (en) * | 2014-03-13 | 2015-09-17 | Sabanci Üniversitesi | Pharmaceutical drug delivery system |
US10166330B2 (en) | 2014-03-13 | 2019-01-01 | Sabanci Üniversitesi | Pharmaceutical drug delivery system |
EP2918263A1 (en) * | 2014-03-13 | 2015-09-16 | Sabanci Üniversitesi | Pharmaceutical drug delivery system |
EP3831438A1 (en) * | 2016-04-29 | 2021-06-09 | Sorrento Therapeutics, Inc. | Microneedle array assembly and fluid delivery apparatus having such an assembly |
WO2017189259A2 (en) | 2016-04-29 | 2017-11-02 | Kimberly-Clark Worldwide, Inc. | Microneedle array assembly and fluid delivery apparatus having such an assembly |
CN109475726A (en) * | 2016-04-29 | 2019-03-15 | 索伦托治疗有限公司 | Microneedle array package, drug delivery device and the method for large area low pressure infusion liquid |
US11745002B2 (en) * | 2016-04-29 | 2023-09-05 | Sorrento Therapeutics, Inc. | Microneedle array assembly and fluid delivery apparatus having such an assembly |
US20220211989A1 (en) * | 2016-04-29 | 2022-07-07 | Sorrento Therapeutics, Inc. | Microneedle array assembly and fluid delivery apparatus having such an assembly |
EP3448494A4 (en) * | 2016-04-29 | 2019-12-25 | Sorrento Therapeutics, Inc. | Microneedle array assembly and fluid delivery apparatus having such an assembly |
US11311708B2 (en) * | 2016-04-29 | 2022-04-26 | Sorrento Therapeutics, Inc. | Microneedle array assembly and fluid delivery apparatus having such an assembly |
CN113198101A (en) * | 2016-04-29 | 2021-08-03 | 索伦托治疗有限公司 | Microneedle array assembly, drug delivery device and method for large area low pressure infusion of liquids |
CN109475726B (en) * | 2016-04-29 | 2021-05-18 | 索伦托治疗有限公司 | Microneedle array assembly, drug delivery device and method for large area low pressure infusion of liquids |
US10869842B1 (en) * | 2016-09-07 | 2020-12-22 | David P Summers | Transdermal delivery of pharmaceutical agents |
US11241563B2 (en) | 2016-12-22 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Microneedle arrays and methods for making and using |
US11510883B2 (en) * | 2017-10-06 | 2022-11-29 | Xobaderm Limited | Kit for delivery of an active compound into the skin |
WO2019069102A1 (en) * | 2017-10-06 | 2019-04-11 | Xobaderm Limited | Kit for delivery of an active compound into the skin |
WO2019194871A1 (en) * | 2018-04-05 | 2019-10-10 | Erbst Steven Robert | Therapeutic elastic bandage for modulating the endocannabinoid system |
WO2020003247A3 (en) * | 2018-06-29 | 2020-03-12 | Johnson & Johnson Consumer Inc. | Three-dimensional microfluidics devices for the delivery of actives |
WO2020003248A1 (en) * | 2018-06-29 | 2020-01-02 | Johnson & Johnson Consumer Inc. | Three-dimensional microfluidics devices for the delivery of actives |
US11413440B2 (en) | 2018-06-29 | 2022-08-16 | Johnson & Johnson Consumer Inc. | Three-dimensional microfluidics devices for the delivery of actives |
US11464955B2 (en) | 2018-06-29 | 2022-10-11 | Johnson & Johnson Consumer Inc. | Three-dimensional microfluidics devices for the delivery of actives |
WO2021003315A1 (en) * | 2019-07-02 | 2021-01-07 | Rowley Clifford T | Transdermal patch providing improved permeability |
Also Published As
Publication number | Publication date |
---|---|
MX2013009591A (en) | 2013-11-04 |
BR112013021282A2 (en) | 2018-06-12 |
CA2825591A1 (en) | 2012-09-07 |
AU2012222971B2 (en) | 2016-01-21 |
RU2013141508A (en) | 2015-04-10 |
KR20140006903A (en) | 2014-01-16 |
CN103384545A (en) | 2013-11-06 |
EP2680918A4 (en) | 2014-08-13 |
JP2014511243A (en) | 2014-05-15 |
US8696637B2 (en) | 2014-04-15 |
EP2680918A2 (en) | 2014-01-08 |
WO2012117302A2 (en) | 2012-09-07 |
WO2012117302A3 (en) | 2012-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8696637B2 (en) | Transdermal patch containing microneedles | |
AU2012222971A1 (en) | Transdermal patch containing microneedles | |
US8636696B2 (en) | Transdermal device containing microneedles | |
US11771878B2 (en) | Microneedle injection and infusion apparatus and method of using same | |
US20150174386A1 (en) | Transdermal device containing microneedles | |
US10695547B2 (en) | Microneedle injection apparatus comprising an inverted actuator | |
EP1301237B1 (en) | Microdevice and method of manufacturing a microdevice | |
RU2630610C2 (en) | Transdermal delivery of high-binded bioactive agents | |
JP4836392B2 (en) | Skin permeation enhancing device for extracting or administering a substance and method for manufacturing the device | |
EP3003458B1 (en) | Microneedle injection apparatus comprising a dual cover | |
US20080167601A1 (en) | Microneedles to be placed in the skin for the transdermal application of pharhmaceuticals | |
CA2546688C (en) | Device for the transdermal administration of active ingredients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KIMBERLY-CLARK WORLDWIDE, INC., WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROSS, RUSSELL F.;REEL/FRAME:026089/0430 Effective date: 20110405 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: KIMBERLY-CLARK WORLDWIDE, INC., WISCONSIN Free format text: NAME CHANGE;ASSIGNOR:KIMBERLY-CLARK WORLDWIDE, INC.;REEL/FRAME:034880/0674 Effective date: 20150101 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551) Year of fee payment: 4 |
|
AS | Assignment |
Owner name: SORRENTO THERAPEUTICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KIMBERLY-CLARK WORLDWIDE, INC.;REEL/FRAME:046899/0689 Effective date: 20180702 |
|
AS | Assignment |
Owner name: OAKTREE FUND ADMINISTRATION, LLC, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:SORRENTO THERAPEUTICS, INC.;TNK THERAPEUTICS, INC.;CONCORTIS BIOSYSTEMS, CORP.;AND OTHERS;REEL/FRAME:047446/0335 Effective date: 20181107 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: TNK THERAPEUTICS, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:OAKTREE FUND ADMINISTRATION, LLC;REEL/FRAME:053368/0577 Effective date: 20200714 Owner name: ARK ANIMAL HEALTH, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:OAKTREE FUND ADMINISTRATION, LLC;REEL/FRAME:053368/0577 Effective date: 20200714 Owner name: CONCORTIS BIOSYSTEMS, CORP., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:OAKTREE FUND ADMINISTRATION, LLC;REEL/FRAME:053368/0577 Effective date: 20200714 Owner name: SORRENTO THERAPEUTICS, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:OAKTREE FUND ADMINISTRATION, LLC;REEL/FRAME:053368/0577 Effective date: 20200714 Owner name: SCINTILLA PHARMACEUTICALS, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:OAKTREE FUND ADMINISTRATION, LLC;REEL/FRAME:053368/0577 Effective date: 20200714 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
AS | Assignment |
Owner name: JMB CAPITAL PARTNERS LENDING, LLC, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNORS:SORRENTO THERAPEUTICS, INC.;SCINTILLA PHARMACEUTICALS, INC.;REEL/FRAME:063283/0063 Effective date: 20230330 |
|
AS | Assignment |
Owner name: SCILEX HOLDING COMPANY, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNORS:SORRENTO THERAPEUTICS, INC.;SCINTILLA PHARMACEUTICALS, INC.;REEL/FRAME:064441/0575 Effective date: 20230728 |
|
AS | Assignment |
Owner name: SCINTILLA PHARMACEUTICALS, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JMB CAPITAL PARTNERS LENDING, LLC;REEL/FRAME:064571/0848 Effective date: 20230809 Owner name: SORRENTO THERAPEUTICS, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JMB CAPITAL PARTNERS LENDING, LLC;REEL/FRAME:064571/0848 Effective date: 20230809 |
|
AS | Assignment |
Owner name: SCINTILLA PHARMACEUTICALS, INC., CALIFORNIA Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:SCILEX HOLDING COMPANY;REEL/FRAME:065017/0844 Effective date: 20230921 Owner name: SORRENTO THERAPEUTICS, INC., CALIFORNIA Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:SCILEX HOLDING COMPANY;REEL/FRAME:065017/0844 Effective date: 20230921 |